Jean–fréderic Colombel‡‡

Jean–fréderic Colombel‡‡'s AcademicInfluence.com Rankings

Philosophy

#2614

World Rank

#4414

Historical Rank

Logic

#672

World Rank

#1173

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jean–fréderic Colombel‡‡ Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jean–fréderic Colombel‡‡'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease (2001) (5565)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (2002) (3884)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. (2005) (2917)
Infliximab for induction and maintenance therapy for ulcerative colitis. (2005) (2903)
Infliximab, azathioprine, or combination therapy for Crohn's disease. (2010) (2727)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (2007) (2091)
Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) (1847)
Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) (1815)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. (2010) (1578)
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. (2004) (1410)
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (2011) (1315)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. (2012) (1244)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. (2004) (1175)
Mapping of a susceptibility locus for Crohn's disease on chromosome 16 (1996) (1046)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) (1026)
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. (2002) (996)
Risk factors for opportunistic infections in patients with inflammatory bowel disease. (2008) (969)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. (2004) (969)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (950)
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (2004) (937)
Natalizumab induction and maintenance therapy for Crohn's disease. (2005) (887)
Ulcerative colitis (2017) (825)
The Natural History of Adult Crohn's Disease in Population-Based Cohorts (2010) (823)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study (2009) (822)
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011) (803)
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. (1998) (803)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. (2012) (793)
Crohn's disease (2017) (759)
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) (744)
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors (2007) (706)
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. (2012) (693)
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial (2016) (666)
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management (2006) (656)
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. (2014) (621)
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. (2000) (609)
The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
European evidence-based Consensus on the management of ulcerative colitis: Current management. (2008) (593)
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. (2012) (577)
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) (573)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. (2008) (559)
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020) (551)
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial (2017) (549)
Natural history of pediatric Crohn's disease: a population-based cohort study. (2008) (544)
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. (2007) (533)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. (2020) (529)
Development of the Crohn's disease digestive damage score, the Lémann score (2010) (511)
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. (2012) (503)
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial (2012) (483)
Geographical variability and environmental risk factors in inflammatory bowel disease (2013) (469)
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. (2009) (464)
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ (2005) (463)
Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. (2003) (454)
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. (2011) (450)
Adherent Invasive Escherichia coli Strains from Patients with Crohn's Disease Survive and Replicate within Macrophages without Inducing Host Cell Death (2001) (447)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (440)
Clinical implications of mucosal healing for the management of IBD (2010) (436)
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011) (435)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. (2009) (410)
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial (2005) (409)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management (2016) (407)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial (2013) (404)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. (2006) (377)
Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer (2001) (374)
Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry (2021) (372)
Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy (2004) (370)
Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis (2003) (358)
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. (2005) (352)
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. (2009) (334)
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. (2009) (333)
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. (2013) (332)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. (2019) (329)
Adherent-invasive Escherichia coli in inflammatory bowel disease (2007) (322)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease (2006) (316)
The value of serologic markers in indeterminate colitis: a prospective follow-up study. (2003) (313)
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. (1999) (312)
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. (2012) (310)
Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. (2008) (306)
Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? (2001) (294)
Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease (2002) (287)
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health (2011) (278)
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. (2016) (276)
Treat to target: a proposed new paradigm for the management of Crohn's disease. (2015) (274)
Antibiotics Associated With Increased Risk of New-Onset Crohn’s Disease But Not Ulcerative Colitis: A Meta-Analysis (2014) (274)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. (2006) (273)
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study (2013) (273)
The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study (2009) (273)
Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999) (2004) (263)
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. (2013) (259)
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. (2017) (257)
Selective expansion of intraepithelial lymphocytes expressing the HLA-E–specific natural killer receptor CD94 in celiac disease☆☆☆ (2000) (255)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium (2016) (250)
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. (2019) (249)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017) (248)
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. (2015) (247)
Specific antibody response to oligomannosidic epitopes in Crohn's disease (1996) (246)
Incidence of inflammatory bowel disease in northern France (1988-1990). (1994) (246)
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. (2011) (245)
Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis (2009) (244)
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease (1999) (242)
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease (1992) (242)
Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and ROR&ggr;t+ Regulatory T Cells and Exacerbate Colitis in Mice (2019) (241)
Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease (2003) (238)
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. (1997) (230)
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. (2007) (226)
Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population-Based Study in Northern France (1988-1999) (2005) (226)
Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. (2016) (224)
Adalimumab induces deep remission in patients with Crohn's disease. (2014) (221)
Effect of IBD medications on COVID-19 outcomes: results from an international registry (2020) (221)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data (2010) (219)
Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease (2016) (219)
Mesenteric fat in Crohn’s disease: a pathogenetic hallmark or an innocent bystander? (2006) (217)
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study (2005) (214)
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. (2003) (213)
Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. (2017) (213)
Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn’s disease: a prospective study (2006) (213)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. (2002) (212)
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease (2012) (208)
Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies (2012) (207)
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease (2011) (205)
Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. (2006) (197)
Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent–invasive E. coli strains isolated from patients with Crohn's disease (2003) (197)
Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. (2003) (196)
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. (2017) (196)
Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease (2014) (194)
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial (2008) (193)
Long‐term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population‐based cohorts (2011) (191)
Ulcerative colitis as a progressive disease: the forgotten evidence. (2012) (190)
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. (2015) (188)
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon (2010) (187)
Clinical characteristics of Crohn's disease in 72 families. (1996) (186)
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. (2013) (184)
Clinical relevance of advances in genetics and pharmacogenetics of IBD. (2004) (184)
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease (2011) (182)
Genotypic and phenotypic analysis of the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European population (1998) (182)
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. (2014) (180)
Candida albicans Colonization and ASCA in Familial Crohn's Disease (2009) (178)
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. (2006) (177)
Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. (2003) (177)
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. (1999) (176)
IBD across the age spectrum—is it the same disease? (2014) (174)
The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10‐ to 19‐year‐old age bracket (1988–2007) (2011) (173)
Complete Genome Sequence of Crohn's Disease-Associated Adherent-Invasive E. coli Strain LF82 (2010) (173)
Indeterminate colitis: A review of the concept — What's in a name? (2008) (170)
Long-term Efficacy of Vedolizumab for Ulcerative Colitis (2016) (168)
Risk factors of anxiety and depression in inflammatory bowel disease (2012) (167)
Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study (2009) (165)
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. (1996) (164)
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
Long-term Efficacy of Vedolizumab for Crohn’s Disease (2016) (164)
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. (2009) (163)
Mucin gene expression in intestinal epithelial cells in Crohn's disease (2001) (161)
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. (2015) (161)
Management of Crohn's disease of the ileoanal pouch with infliximab (2003) (160)
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. (2010) (160)
Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients (2001) (160)
Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). (2013) (157)
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. (2013) (157)
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis (2015) (157)
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol (2012) (155)
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. (1986) (153)
Molecular inventory of faecal microflora in patients with Crohn's disease. (2003) (151)
Urbanization and the gut microbiota in health and inflammatory bowel disease (2018) (150)
Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. (2010) (150)
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. (2013) (149)
Point Mutations in FimH Adhesin of Crohn's Disease-Associated Adherent-Invasive Escherichia coli Enhance Intestinal Inflammatory Response (2013) (148)
Enterocolitis due to immune checkpoint inhibitors: a systematic review (2018) (147)
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. (2010) (147)
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. (1996) (143)
Multilocus Sequence Typing Reveals Intrafamilial Transmission and Microevolutions of Candida albicans Isolates from the Human Digestive Tract (2006) (142)
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review (2019) (141)
Mycobiota in gastrointestinal diseases (2015) (139)
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 (2014) (137)
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review (2019) (136)
Value of wireless capsule endoscopy in patients with indeterminate colitis (inflammatory bowel disease type unclassified) (2007) (136)
Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. (2014) (136)
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids (2016) (135)
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. (2015) (135)
The forgotten role of lymphangitis in Crohn’s disease (2007) (134)
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. (2018) (133)
Aseptic Abscesses: A Study of 30 Patients With or Without Inflammatory Bowel Disease and Review of the Literature (2007) (131)
Natural history of eosinophilic gastroenteritis. (2011) (131)
Anti-Saccharomyces cerevisiae Mannan Antibodies in Familial Crohn's Disease (1998) (130)
Abatacept for Crohn's disease and ulcerative colitis. (2012) (130)
Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study (2010) (130)
Fecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease (1997) (128)
Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? (2017) (127)
Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease (2012) (127)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials (2019) (126)
751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy (2009) (126)
Inflammatory bowel disease in spouses and their offspring. (2001) (125)
Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case–Control Study (2007) (125)
Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. (1989) (123)
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. (2014) (123)
Quality Indicators for Inflammatory Bowel Disease: Development of Process and Outcome Measures (2013) (123)
Adalimumab safety in global clinical trials of patients with Crohn's disease (2009) (122)
Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease (2017) (119)
Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer (2013) (119)
ICCE consensus for inflammatory bowel disease. (2005) (118)
Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease (2012) (116)
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. (2020) (116)
Inflammatory bowel disease and the elderly: a review. (2015) (115)
Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. (1995) (113)
Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. (1988) (112)
Crohn's disease: beyond antagonists of tumour necrosis factor (2008) (111)
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. (2016) (110)
Gut microbiota density influences host physiology and is shaped by host and microbial factors (2018) (110)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. (2018) (109)
Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. (2019) (109)
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. (2015) (109)
Evidence of lymphocyte alveolitis in Crohn's disease. (1985) (107)
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort (2015) (107)
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. (2016) (107)
Adalimumab for the treatment of fistulas in patients with Crohn’s disease (2009) (106)
The features of mucosa‐associated microbiota in primary sclerosing cholangitis (2016) (106)
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study (2016) (106)
Methotrexate in Crohn's disease: long-term efficacy and toxicity (2000) (105)
Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (105)
Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. (1996) (104)
Optimising monitoring in the management of Crohn's disease: a physician's perspective. (2013) (104)
Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery (2015) (103)
Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease (2011) (103)
Systematic review: fertility in non‐surgically treated inflammatory bowel disease (2013) (102)
Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD (2014) (101)
Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice (2019) (101)
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study (2015) (100)
A simple biological score for predicting low risk of short‐term relapse in Crohn's disease (2006) (100)
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease (2001) (99)
Intravenous cyclosporine in attacks of ulcerative colitis (1996) (99)
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease (2010) (99)
Biologics in inflammatory bowel disease: what are the data? (2015) (99)
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial (2017) (99)
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. (2017) (99)
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis (2007) (99)
Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC (2016) (98)
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. (2021) (98)
Long‐term outcome of treatment with infliximab in pediatric‐onset Crohn's disease: A population‐based study (2011) (98)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE (2013) (98)
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases (2016) (96)
P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (2008) (96)
IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. (2019) (96)
Early Crohn disease: a proposed definition for use in disease-modification trials (2010) (95)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease (2018) (94)
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. (2019) (94)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety (2011) (94)
Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. (1997) (92)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process (2012) (92)
Development of an index to define overall disease severity in IBD (2016) (92)
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms (2021) (92)
Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experience (2011) (92)
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation (2005) (91)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study (2006) (90)
Acute graft-versus-host disease of the gut: considerations for the gastroenterologist (2017) (89)
Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis (2016) (89)
Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial (2009) (89)
Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. (2013) (89)
Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health (2010) (89)
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. (2020) (87)
Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future (2013) (87)
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials (2017) (85)
A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis (2003) (84)
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 y Before Diagnosis. (2020) (84)
Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? (1994) (83)
Serological markers in inflammatory bowel diseases. (2003) (83)
Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease (2011) (83)
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention (2018) (82)
Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest (2017) (82)
Secukinumab failure in Crohn's disease: the yeast connection? (2012) (82)
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. (2016) (82)
P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm (2007) (81)
The Role of Early Biologic Therapy in Inflammatory Bowel Disease. (2019) (81)
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis (2010) (81)
ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression (2005) (80)
Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. (1998) (80)
Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice (2013) (80)
IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 ‐ Inflammatory bowel disease task force meeting (2011) (80)
Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis (2011) (80)
Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. (2020) (79)
Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. (2012) (78)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. (2018) (77)
Risk Factors Associated With Small Bowel Adenocarcinoma in Crohn's Disease: A Case–Control Study (2008) (77)
Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics (2011) (77)
Probiotics in inflammatory bowel disease: a critical review. (2003) (76)
Association of HLA class II genes with susceptibility to Crohn's disease. (1996) (76)
Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. (1997) (75)
Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. (2006) (75)
Environmental Factors in Familial Crohn's Disease in Belgium (2005) (75)
Factors associated with short- and long-term outcomes of therapy for Crohn's disease. (2015) (74)
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. (2014) (74)
Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders (2018) (73)
Improving quality of care in inflammatory bowel disease: what changes can be made today? (2014) (72)
protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. (2019) (71)
TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort (2009) (71)
Systematic review: safety of mesalazine in ulcerative colitis (2018) (71)
The intestinal barrier, an arbitrator turned provocateur in IBD (2020) (70)
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy (2016) (69)
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis (2006) (68)
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease (2017) (68)
A phase II study of laquinimod in Crohn's disease (2014) (68)
Increased pulmonary and intestinal permeability in Crohn's disease. (1992) (68)
Lymphatics, tertiary lymphoid organs and the granulomas of Crohn’s disease: an immunohistochemical study (2011) (67)
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease (2018) (67)
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies (2021) (67)
Corrigendum: Polymorphisms in the Mannose-Binding Lectin Gene are Associated with Defective Mannose-Binding Lectin Functional Activity in Crohn’s Disease Patients (2016) (66)
Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial (2005) (66)
Identifying strains that contribute to complex diseases through the study of microbial inheritance (2015) (66)
Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. (2017) (66)
Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis (2015) (66)
Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID (2014) (65)
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. (2010) (65)
Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine (2011) (65)
Antibodies against Glucan, Chitin, and Saccharomyces cerevisiae Mannan as New Biomarkers of Candida albicans Infection That Complement Tests Based on C. albicans Mannan (2008) (65)
Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease (2004) (65)
New therapeutic avenues in ulcerative colitis: thinking out of the box (2013) (64)
The 10 remaining mysteries of inflammatory bowel disease (2007) (64)
Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases (2019) (64)
AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. (2019) (64)
Small Bowel Adenocarcinomas Complicating Crohn's Disease Are Associated With Dysplasia: A Pathological and Molecular Study (2014) (64)
Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee (2014) (64)
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study (2001) (64)
What Should Gastroenterologists and Patients Know About COVID-19? (2020) (63)
961 Infliximab Discontinuation in Crohn's Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study (2009) (63)
Inflammatory Bowel Disease and Pancreatitis: A Review. (2016) (62)
751e Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease – First Results of the Extend Trial (2009) (62)
Abnormalities in mucin gene expression in Crohn's disease. (1999) (62)
Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease (2020) (62)
Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease (2018) (62)
CARD4/NOD1 is not involved in inflammatory bowel disease (2003) (62)
Anti-Saccharomyces cerevisiae mannan antibodies in familial crohn’s disease (1998) (62)
Cyclosporine treatment of steroid‐refractory ulcerative colitis during pregnancy (2009) (61)
Methotrexate in Crohn's disease: long-term efficacy and toxicity. (2000) (61)
Post Hoc Analysis (2022) (61)
Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-α secretion (2012) (60)
[Bacterial translocation in Crohn disease]. (1992) (60)
Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis Do the Benefits Outweigh the Risks? (2015) (59)
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials (2018) (59)
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission (2017) (59)
Abnormalities in mucin gene expression in Crohn's disease (1999) (59)
In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. (2003) (59)
Lymphoid Aggregates Remodel Lymphatic Collecting Vessels that Serve Mesenteric Lymph Nodes in Crohn Disease. (2016) (58)
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. (2017) (58)
Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. (2016) (58)
Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease (2020) (57)
Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab (2016) (57)
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease (2018) (56)
Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. (2005) (56)
Pathogenic agents in inflammatory bowel diseases (2008) (56)
Extractible self-expandable metal stent in the treatment of Crohn’s disease anastomotic strictures (2012) (56)
Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease (2009) (56)
Mortality and Cancer in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Study (2013) (56)
Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies (2021) (55)
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives (2018) (55)
Long‐term safety of vedolizumab for inflammatory bowel disease (2020) (55)
Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. (2011) (54)
Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. (2013) (54)
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. (2018) (54)
PPAR-gamma in ulcerative colitis: a novel target for intervention. (2013) (53)
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open (2019) (53)
Relevance of serologic studies in inflammatory bowel disease (2004) (53)
Escalation to weekly dosing recaptures response in adalimumab‐treated patients with moderately to severely active ulcerative colitis (2014) (52)
Perioperative endoscopy of the whole small bowel in Crohn's disease. (1993) (52)
Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities (2016) (51)
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease (2015) (51)
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. (2012) (50)
Impact of surgery on quality of life in Crohn's disease. (1997) (50)
Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis (2017) (50)
The management of immunosuppression in patients with inflammatory bowel disease and cancer (2013) (50)
Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. (2013) (49)
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. (2020) (49)
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. (2019) (49)
Activated eosinophils in adult coeliac disease: evidence for a local release of major basic protein. (1992) (49)
Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease (2016) (49)
Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease (2017) (49)
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals (2018) (49)
Evolving Definitions of Remission in Crohn’s Disease (2013) (49)
Role of mannose-binding lectin in intestinal homeostasis and fungal elimination (2015) (48)
The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? (2009) (48)
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. (2016) (48)
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS] (2015) (47)
Mapping of inflammatory bowel disease in northern France: Spatial variations and relation to affluence (2010) (47)
Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study (2017) (46)
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease (2006) (46)
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease (2010) (46)
Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease (2005) (46)
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. (1994) (45)
Cap polyposis occurring in the postoperative course of pelvic surgery. (1994) (45)
Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. (1992) (45)
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry (2020) (45)
Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial (2011) (44)
Short Bowel Syndrome and Intestinal Failure in Crohn's Disease (2016) (44)
Defined microbiota transplant restores Th17/RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas (2019) (44)
Deep Remission: A New Concept? (2013) (44)
Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn’s Disease (2018) (44)
Granulomas obstruct lymphatics in all layers of the intestine in Crohn's disease (2014) (44)
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. (2018) (43)
O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFN&agr;: UNITI-1 (2016) (43)
Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. (2004) (43)
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. (2018) (43)
Genotype/Phenotype Analyses for 53 Crohn’s Disease Associated Genetic Polymorphisms (2012) (43)
Decreased Lymphatic Vessel Density Is Associated With Postoperative Endoscopic Recurrence in Crohn’s Disease (2013) (43)
High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. (2015) (42)
The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils (2015) (42)
Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing: A Post hoc Analysis from SONIC (2015) (42)
Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis (2014) (42)
Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial. (2021) (42)
No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases (2018) (41)
Bacterial translocation in patients with colorectal cancer. (1988) (41)
Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease. (1995) (41)
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists. (2021) (40)
Yeasts: Neglected Pathogens (2010) (40)
Long-term Outcome After First Intestinal Resection in Pediatric-onset Crohn's Disease: A Population-based Study (2013) (40)
818 Excess Risk of Lymphoproliferative Disorders (LPD) in Inflammatory Bowel Diseases (IBD): Interim Results of the Cesame Cohort (2008) (40)
Functional gastrointestinal symptoms in patients with inflammatory bowel disease: A clinical challenge (2018) (39)
Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? (2019) (39)
Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement (2015) (39)
Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease (2016) (39)
Familial aggregation and antimicrobial response dose‐dependently affect the risk for Crohn's disease (2010) (39)
Gastrointestinal involvement attenuates COVID-19 severity and mortality (2020) (39)
Features of Patients With Crohn's Disease and Hidradenitis Suppurativa. (2016) (39)
Interobserver Variation Study of the Rutgeerts Score to Assess Endoscopic Recurrence after Surgery for Crohn's Disease. (2016) (39)
Challenges in IBD Research: Preclinical Human IBD Mechanisms. (2019) (38)
Pouchitis Is Associated with Mucosal Imbalance Between Interleukin‐8 and Interleukin‐10 (2000) (38)
Similar IL-5, IL-3, and GM-CSF syntheses by eosinophils in the jejunal mucosa of patients with celiac disease and dermatitis herpetiformis. (1998) (38)
Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? (2015) (38)
Systematic review and meta‐analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease (2020) (38)
An immunological link between Candida albicans colonization and Crohn’s disease (2015) (38)
943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial (2012) (38)
GipA Factor Supports Colonization of Peyer's Patches by Crohn's Disease-associated Escherichia Coli (2016) (38)
Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial (2016) (38)
Anti‐Neutrophil Cytoplasmic Auto‐Antibodies (ANCA) in Ulcerative Colitis (UC): No Relationship with Disease Activity (2000) (38)
Activated eosinophils in inflammatory bowel disease: do they matter? (1999) (38)
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. (2015) (37)
Clinical predictors at diagnosis of disabling pediatric Crohn's disease (2012) (37)
Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009 (2013) (37)
Epithelial inflammation response induced by Shigella flexneri depends on mucin gene expression. (2002) (37)
Increased intestinal permeability in active pulmonary sarcoidosis. (1992) (37)
Transition of Inflammatory Bowel Disease Care: Assessment of Transition Readiness Factors and Disease Outcomes in a Young Adult Population (2016) (37)
Farnesoid X Receptor Expression Is Decreased in Colonic Mucosa of Patients with Primary Sclerosing Cholangitis and Colitis-associated Neoplasia (2013) (36)
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease (2020) (36)
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases (2020) (36)
Portomesenteric Vein Thrombosis in Patients With Inflammatory Bowel Disease (2013) (35)
Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States (2014) (35)
Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts (2018) (35)
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis (2019) (35)
Antimycobacterial therapy in Crohn's disease: game over? (2007) (35)
Patient‐Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta‐analysis (2019) (35)
Nitrate-Reducing Bacteria in Diversion Colitis (A Clue to Inflammation?) (1997) (35)
Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. (2016) (34)
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis (2020) (34)
Humoral Immunity Links Candida albicans Infection and Celiac Disease (2015) (34)
Role of the High Affinity Immunoglobulin E Receptor in Bacterial Translocation and Intestinal Inflammation (2001) (34)
Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. (2019) (34)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (2016) (34)
Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis (2018) (34)
Genetics and phenotypes in inflammatory bowel disease (2016) (33)
Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease (2016) (33)
Functional Polymorphisms in the Regulatory Regions of the VNN1 Gene Are Associated with Susceptibility to Inflammatory Bowel Diseases (2013) (33)
Clustering of Crohn's disease within affected sibships (2003) (33)
Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis (2019) (33)
Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort (2017) (33)
Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy: Results of the GAIN Study (2006) (33)
Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis—a Systematic Review and Meta-analysis (2019) (33)
Advances and perspectives in the genetics of inflammatory bowel diseases. (2006) (33)
A characterization of pro‐inflammatory cytokines in dextran sulfate sodium‐induced chronic relapsing colitis mice model (2018) (33)
Familial expression of anti- Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study (2001) (32)
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. (2018) (32)
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications (2020) (32)
Sex‐based differences in the incidence of inflammatory bowel diseases—pooled analysis of population‐based studies from the Asia‐Pacific region (2019) (32)
Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. (2019) (32)
Pancreatic changes in TNBS-induced colitis in mice. (2003) (32)
The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease (2017) (32)
Endoscopic Mucosal improvement in patients with active Crohn's Disease treated with Certolizumab Pegol: First results of the MUSIC Clinical Trial (2008) (32)
Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes (2021) (32)
[Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate]. (2002) (32)
Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial (2016) (32)
Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease. (1995) (32)
Hidradenitis suppurativa and Crohn's disease in two families: a significant association? (1992) (31)
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. (2020) (31)
Skin Side Effects of Inflammatory Bowel Disease Therapy (2013) (31)
Anti-neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis. (1992) (30)
Abnormal mucus in cap polyposis (1998) (30)
Bacterial translocation in colorectal cancers. (1990) (30)
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study. (2019) (30)
Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. (2011) (29)
Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011 (2017) (29)
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases (2016) (29)
Association of coeliac disease and portal venous thrombosis. (1995) (29)
Acute exposure of small intestine to ethanol induces mucosal leakage and prostaglandin E2 synthesis. (1992) (29)
Review article: bacteriophages in gastroenterology—from biology to clinical applications (2019) (29)
Diet Modifies Colonic Microbiota and CD4+ T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23. (2018) (29)
943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC (2012) (28)
Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial (2006) (28)
The risk for opportunistic infections in inflammatory bowel disease with biologics: an update (2018) (28)
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry (2021) (28)
Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review. (2015) (28)
Detection of Antisynthetic Mannoside Antibodies (AΣMA) Reveals Heterogeneity in the ASCA Response of Crohn's Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction (2008) (27)
Hyaluronic acid and type III procollagen peptide in jejunal perfusion fluid as markers of connective tissue turnover. (1989) (27)
Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study (2012) (27)
281 Thiopurine Therapy Is Associated with a Three-Fold Decrease in the Incidence of Advanced Colorectal Neoplasia in IBD Patients with Longstanding Extensive Colitis: Results from the CESAME Cohort (2009) (27)
Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study (2017) (27)
494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study (2008) (27)
[Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease]. (2000) (27)
OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis (2019) (27)
Search for evidence of recurring or persistent viruses in Crohn's disease (2007) (26)
Sweet's syndrome associated with Crohn's disease. (1989) (26)
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease (2009) (26)
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ (2013) (26)
Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
Do pANCA define a clinical subgroup in patients with Crohn's disease? (1997) (25)
Changing epidemiology of immune-mediated inflammatory diseases in immigrants: a systematic review of population-based studies (2019) (25)
Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm (2017) (25)
TAP gene transporter polymorphism in inflammatory bowel diseases. (1997) (25)
Systematic review: gastrointestinal infection and incident inflammatory bowel disease (2020) (25)
Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis (2019) (25)
Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer (2007) (25)
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis (2018) (24)
Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. (2012) (24)
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. (2015) (24)
Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance (2019) (24)
Higher Remission and Maintenance of Response Rates with Subcutaneous Monthly Certolizumab Pegol in Patients with Recent-Onset Crohnʼs Disease: Data from PRECiSE 2 (2006) (24)
A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) (2004) (24)
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials (2018) (24)
Systematic review with meta‐analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease (2019) (24)
Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD (2021) (24)
Variants of NOD1 and NOD2 genes display opposite associations with familial risk of crohn's disease and anti‐saccharomyces cerevisiae antibody levels (2012) (24)
The Management of Intestinal Penetrating Crohn's Disease. (2018) (24)
Autoimmune and Chronic Inflammatory Disease Patients with COVID‐19 (2021) (23)
Biological markers of short term relapse in Crohn's disease (CD) (2001) (23)
Mother to child transmission of anti- S cerevisiae mannan antibodies (ASCA) in non-IBD families (2000) (23)
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study (2020) (23)
Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. (2016) (23)
First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: Identification of a loss‐of‐function variant (2004) (23)
Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. (2019) (23)
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies (2019) (23)
The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? (2003) (23)
Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn’s Disease Recurrence (2016) (23)
Longitudinal Changes in Fecal Calprotectin Levels among Pregnant Women with and without Inflammatory Bowel Disease and Their Babies. (2020) (23)
T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND (2010) (23)
No Evidence for an Involvement of the P38 and JNK Mitogen-Activated Protein in Inflammatory Bowel Diseases (2006) (22)
Diffusion and perfusion MRI quantification in ileal Crohn’s disease (2018) (22)
Familial Crohn's Disease in Belgium: Pedigrees, Temporal Relationships Among Cases, and Family Histories (2007) (22)
Treating Inflammatory Bowel Disease With Diet: A Taste Test. (2019) (22)
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. (2016) (22)
Increased Risk of Oral Cancer in Patients With Inflammatory Bowel Diseases. (2016) (22)
Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis (2011) (22)
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study (2018) (22)
Jejunal immunoglobulin and antigliadin antibody secretion in adult coeliac disease. (1990) (22)
Editorial: Antibiotics Earlier, IBD Later? (2010) (21)
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis (2020) (21)
Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses (2021) (21)
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. (2019) (21)
Postoperative Complications in Pediatric Inflammatory Bowel Disease: A Population-based Study (2016) (21)
979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data (2013) (21)
Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure. (1996) (21)
[Infliximab therapy for Crohn's disease anoperineal lesions]. (2008) (21)
Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. (2011) (20)
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. (2019) (20)
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension (2018) (20)
Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): Long-term follow-up of patients (1998) (20)
Decreased faecal exoglycosidase activities identify a subset of patients with active Crohn's disease. (1992) (20)
Targeting B cells for inflammatory bowel disease treatment: back to the future. (2020) (20)
Bariatric surgery is associated with increased risk of new‐onset inflammatory bowel disease: case series and national database study (2018) (20)
Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary (2016) (20)
Dysphagia revealing esophageal and gastric metastases of renal carcinoma. (1995) (20)
IBD in 2010: Optimizing treatment and minimizing adverse events (2011) (20)
Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? (1996) (20)
COLLAGENOUS COLITIS IS ASSOCIATED WITH HLA SIGNATURE AND SHARES GENETIC RISKS WITH OTHER IMMUNE-MEDIATED DISEASES. (2020) (20)
Massive plasma cell infiltration of the digestive tract: Secretory component as the rate-limiting factor of immunoglobulin secretion in external fluids (1988) (20)
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. (2012) (20)
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease (2014) (20)
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? (2018) (20)
Remission of myasthenia gravis after proctocolectomy in a patient with ulcerative colitis. (1993) (20)
Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522 (2012) (20)
Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies. (2015) (19)
Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease. (1988) (19)
Oxidative and synthetic functions of n-butyrate in colonocytes (1992) (19)
Association of an attack of varicella and an achalasia. (1995) (19)
Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn’s Disease: A Pilot Study (ACROHNEM) (2019) (19)
What are the major arguments in favour of the genetic susceptibility for inflammatory bowel disease? (2003) (19)
Circulating growth-regulator oncogene alpha contributes to neutrophil priming and interleukin-8-directed mucosal recruitment into chronic lesions of patients with Crohn's disease. (1999) (19)
Cholecystokinin release and biliopancreatic secretion in response to selective perfusion of the duodenal loop with aminoacids in man. (1988) (19)
Simultaneous determination of pulmonary and intestinal permeability in patients with alcoholic liver cirrhosis (2001) (19)
Viewpoint: Inflammatory bowel diseases among immigrants from low- to high-incidence countries: opportunities and considerations. (2020) (19)
[Chronic interstitial nephritis and mesalazine: 3 new cases?]. (1998) (19)
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients (2021) (19)
921 Long Term Follow-Up of a Cohort of Steroid-Dependent Crohn's Disease Patients Included in a Randomized Trial Evaluating Short Term Infliximab Combined with Azathioprine (2008) (19)
[Incidence of inflammatory bowel diseases in children in the Nord-Pas-de-Calais region]. (1991) (19)
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial (2019) (18)
Immunohistochemical search for viral and bacterial antigens in Crohn's disease. (2013) (18)
768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI (2016) (18)
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry (2021) (18)
[Epidemiology and risk factors of inflammatory bowel diseases]. (2005) (18)
Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. (2005) (17)
Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease. (2021) (17)
The value of pANCA as a serological marker for ulcerative colitis in different European regions (1994) (17)
745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial (2015) (17)
Fecal calprotectin in Crohn's disease: new family ties. (2003) (17)
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease (2019) (17)
946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry (2008) (17)
Antineutrophil cytoplasmic auto-antibodies in sera from patients with ulcerative colitis after proctocolectomy with ileo-anal anastomosis. (1993) (17)
255 Aminosalicylates, Thiopurines and the Risk of Colorectal Cancer in Inflammatory Bowel Diseases: A Case-Control Study Nested in the CESAME Cohort (2010) (17)
Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. (1999) (17)
[What is the prognosis in unclassified colitis? Results of a cohort study of 104 patients in the Northern-Pas-de-Calais region]. (1993) (17)
Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis (2017) (17)
943c ACCELERATED STEP-CARE THERAPY WITH EARLY AZATHIOPRINE (AZA) VS. CONVENTIONAL STEP-CARE THERAPY IN CROHN'S DISEASE. A RANDOMIZED STUDY. (2012) (17)
Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in patients with ulcerative colitis (UC): influence of disease activity and familial study. (1993) (17)
Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD) (2000) (16)
Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? (2011) (16)
Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature. (2016) (16)
Ulcerative colitis as a sole mucosal disease: another misunderstanding? (2011) (16)
The safety profile of infliximab for Crohn's disease in clinical practice: The Mayo clinic experience in 500 patients (2003) (16)
The relationship of granulomas to blood vessels in intestinal Crohn's disease. (1995) (16)
Sa1271 Efficacy of Vedolizumab With Concomitant Corticosteroid or Immunomodulator Use in Patients With Ulcerative Colitis From GEMINI 1 (2015) (16)
Sa1270 Efficacy of Vedolizumab With Concomitant Corticosteroid or Immunomodulator Use in Patients With Crohn's Disease From GEMINI 2 (2015) (16)
Familial Crohn's disease in multiple siblings: no linkage to the HLA system. (1989) (16)
Chemotherapy Tolerance and Oncologic Outcomes in Patients With Colorectal Cancer With and Without Inflammatory Bowel Disease (2017) (16)
Analysis of single nucleotide polymorphisms in the region of CLDN2-MORC4 in relation to inflammatory bowel disease. (2013) (16)
[Comparison of the implantation and metabolic activity of human and rat fecal flora administered to axenic rats]. (1989) (16)
OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM (2019) (16)
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multi-Center Study from the TROPIC consortium. (2020) (16)
Perioperative endoscopy of the whole small bowel in Crohn's disease. (1993) (16)
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. (2020) (16)
SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges (2021) (16)
Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults (2008) (16)
Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (16)
Delineation of Crohn’s Disease Trajectories Using Change in Lémann Index: A Natural History Study (2016) (16)
Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease (2020) (16)
Space-time clusters of Crohn’s disease in northern France (2013) (16)
Aging and IBD: A New Challenge for Clinicians and Researchers. (2021) (16)
Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice (2005) (16)
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. (2021) (15)
Peroxisome proliferator‐activated receptor gamma (PPARγ) regulates lactase expression and activity in the gut (2017) (15)
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores]. (1999) (15)
Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. (2020) (15)
The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review (2021) (15)
S1045 Endoscopic Mucosal Improvement in Patients With Active Crohn's Disease Treated With Certolizumab Pegol: Week 10 and 54 Results of the Music Trial (2010) (15)
Colitis: Diagnosis and Therapeutic Strategies (2006) (15)
Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Naive Crohn's Disease. (2021) (15)
The Role of Anti(myco)bacterial Interventions in the Management of IBD: Is There Evidence at All? (2012) (15)
Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. (2001) (15)
Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics (2019) (15)
Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. (1999) (14)
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. (2016) (14)
Genetic Predictors of Benign Course of Ulcerative Colitis—A North American Inflammatory Bowel Disease Genetics Consortium Study (2016) (14)
Measuring Disability in IBD: The IBD Disability Index. (2013) (14)
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study (2020) (14)
IgM-specific measles-virus antibody in families with a high frequency of Crohn's disease (1995) (14)
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. (2020) (14)
Infliximab failure in cap polyposis (2005) (14)
Efficacy and Safety of Adalimumab After Infliximab Failure in Pediatric Crohn Disease (2015) (14)
The CARD8 p.C10X mutation associates with a low anti-glycans antibody response in patients with Crohn’s disease (2013) (14)
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases (2016) (14)
[Incidence of inflammatory bowel disease in the Nord-Pas-de-Calais region and the Somme area of France in 1988]. (1990) (14)
Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. (2013) (14)
Evidence for a functional genetic polymorphism of the Rho-Gtpase Rac1: Implication in azathioprine response? (2011) (14)
Human herpesvirus‐6 in patients with Crohn’s disease (2010) (14)
A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design (2020) (14)
Chronic gastritis: prevalence in the French population. CIRIG. (1993) (14)
Decade in review—IBD: IBD—genes, bacteria and new therapeutic strategies (2014) (14)
Stopping 5-Aminosalicylate Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. (2020) (14)
Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. (2004) (13)
Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk (2017) (13)
9 Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial (2013) (13)
Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis (2013) (13)
Erratum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 (Nature Genetics (2011) 43 (246-252)) (2011) (13)
Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. (2001) (13)
Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease (2001) (13)
Differentiation and identification of human faecal anaerobic bacteria producing β-galactosidase (a new methodology) (1996) (13)
M1190 Natural History of Eosinophilic Gastroenteritis (2009) (13)
Fluorescence endoscopic imaging study of anastomotic recurrence of Crohn's disease. (1996) (13)
Colonic xanthelasma due to glyceride accumulation associated with an adenoma. (1997) (13)
[The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease. Presentation of 1 case and review of the literature]. (1998) (13)
OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis (2018) (13)
[Cyclo 3 Fort-induced lymphocytic colitis associated with ileal villous atrophy]. (2000) (13)
Massive plasma cell infiltration of the digestive tract. Secretory component as the rate-limiting factor of immunoglobulin secretion in external fluids. (1988) (13)
Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel disease (2001) (13)
Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? (2014) (13)
561 Successive Treatment with Cyclosporine and Infliximab in Severe Ulcerative Colitis (UC) (2009) (13)
A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease (2016) (13)
Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data. (2019) (13)
Early vascular changes in Crohn's disease: an endoscopic fluorescence study. (2000) (13)
OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD) (2018) (12)
Pathogenic Escherichia coli in inflammatory bowel diseases Proceedings of the 1st International Meeting on E. coli and IBD, June 2007, Lille, France. (2008) (12)
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio‐economic factors (2019) (12)
Chronic pancreatitis: a complication of sarcoidosis? (1996) (12)
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis. (2020) (12)
Jejunal immunoglobulin secretion in alcoholic patients with and without cirrhosis. (1991) (12)
Sustained Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease with Adalimumab, Regardless of Anti-TNF History or Concomitant Immunosuppressant Therapy: 1173 (2006) (12)
Polymorphisms in the Mannose-Binding Lectin Gene are Associated with Defective Mannose-Binding Lectin Functional Activity in Crohn’s Disease Patients (2016) (12)
Herpes Simplex Virus Meningoencephalitis in a Patient With Crohn's Disease on Azathioprine Therapy (2010) (12)
IBD in the COVID-19 era: the value of international collaboration (2020) (12)
Clinical updates on perianal fistulas in Crohn’s disease (2018) (12)
Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. (2018) (12)
NOD 2 / CARD 15 Does Not Influence Response to Infliximab in Crohn ' s Disease * (2009) (12)
[Anti-glycan antibodies establish an unexpected link between C. albicans and Crohn disease]. (2009) (12)
Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence. (2019) (12)
Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study (2017) (12)
OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study (2019) (12)
Neutrophil and eosinophil involvement of the small bowel affected by chronic alcoholism. (1988) (12)
Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study (2020) (12)
Are we improving disease outcomes in IBD? A view from the epidemiology side (2013) (12)
Human CYP4F12 genetic polymorphism: identification and functional characterization of seven variant allozymes. (2004) (12)
Endoscopic healing of Crohn's Ileo-colitis with azathioprine (2003) (12)
11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial (2013) (12)
[Campylobacter pylori and gastric acidity]. (1988) (11)
[Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis]. (2008) (11)
Validation and update of the Lémann index to measure cumulative structural bowel damage in Crohn's disease. (2021) (11)
Effect of intrajejunal elemental diet perfusion on jejunal secretion of immunoglobulins, albumin, and hyaluronan in man. (1992) (11)
Incidence of inflammatory bowel disease in northwestern France. Preliminary results in region Nord-Pas-de-Calais. (1989) (11)
Review article: the intersection of mucosal pathophysiology in HIV and inflammatory bowel disease, and its implications for therapy (2014) (11)
Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case–control study (2009) (11)
De-escalation of Therapy in Inflammatory Bowel Disease (2018) (11)
Immunosuppression in inflammatory bowel disease: how much is too much? (2012) (11)
Utility of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), anti-saccharomyces cerevisiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (2000) (11)
Long-term follow-up of strictureplasty in Crohn's disease. (1994) (11)
Economic Impact of Deep Remission in Adalimumab-Treated Patients With Crohn's Disease: Results From Extend (2011) (11)
[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. (2014) (11)
Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease. (2016) (11)
Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease (2003) (11)
Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity (2019) (11)
Epicutaneous Tolerance Induction to a Bystander Antigen Abrogates Colitis and Ileitis in Mice (2017) (11)
416a – Vedolizumab Shows Superior Efficacy Versus Adalimumab: Results of Varsity—The First Head-To-Head Study of Biologic Therapy for Moderate-To-Severe Ulcerative Colitis (2019) (11)
P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study (2019) (10)
143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab (2009) (10)
Crohn's disease patients' and gastroenterologists' perspectives towards de-escalating inflammatory bowel disease therapy. (2019) (10)
643 Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (10)
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management (2020) (10)
Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND: 1190 (2010) (10)
[Presence paf-acether mediator of inflammation in stools of patients with inflammatory enterocolitis]. (1991) (10)
Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542 (2012) (10)
Efficient long‐term depletion of CD20+ B cells by rituximab does not affect gut‐resident plasma cells (2018) (10)
[Intestinal flora and Crohn's disease]. (2003) (10)
M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial (2008) (10)
Week 6 Calprotectin Best Predicts Likelihood of Long-Term Endoscopic Healing in Crohn's Disease: A Post-Hoc Analysis of the UNITI/IM-UNITI Trials. (2020) (10)
Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. (2021) (10)
T1048 No New Safety Signals Identified in Crohn's Disease Patients Treated with Infliximab in An Interim Review of the ENCORE Registry (2008) (10)
Virus serology in familial Crohn disease. (2000) (10)
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. (2019) (10)
Idiopathic acute pancreatitis and sarcoidosis. (1995) (10)
OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis (2018) (10)
693 Azathioprine Dose Reduction in Inflammatory Bowel Disease Patients on Combination Therapy: A Prospective Study (2016) (10)
Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium (2017) (10)
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry (2020) (10)
Mixed adenocarcinoid tumor and Crohn's disease. (1998) (10)
Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study (2019) (10)
Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) (2021) (10)
Impact of Concomitant Endometriosis on Phenotype and Natural History of Inflammatory Bowel Disease (2016) (10)
DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium. (2017) (10)
[Role of antibiotics in Crohn's disease]. (1999) (9)
Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy (2021) (9)
Su1762 Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) Immunochip Study (2013) (9)
Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2: O-006. (2008) (9)
Sarcoidosis and achalasia: a fortuitous association? (1996) (9)
DOP076 Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab (2014) (9)
Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State: 1200 (2010) (9)
Paf-acether in stool as marker of intestinal inflammation (1992) (9)
Evaluation of ileal Crohn’s disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results (2020) (9)
Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. (2020) (9)
Efficacy of sacral nerve stimulation for poor functional results of J-pouch ileoanal anastomosis (2014) (9)
[Acute hemorrhagic colitis induced by glutaraldehyde after colonoscopy]. (1996) (9)
Deglycosylation of α1-proteinase inhibitor is impaired in the faeces of patients with active inflammatory bowel disease (Crohn's disease) (1991) (9)
Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases (2003) (9)
78 Longitudinal Status of Serological Markers Predict Crohn's Disease Phenotype Before Diagnosis: A ‘PREDICTS’ Study (2015) (9)
[Quality of life in chronic inflammatory bowel diseases. Validation of a questionnaire and first French data]. (1996) (9)
Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab. (2007) (9)
RIP2 polymorphisms in inflammatory bowel diseases. (2011) (9)
Gastric emptying of OROS tablets in man (1984) (9)
Serological response to COVID-19 vaccination in IBD patients receiving biologics (2021) (9)
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy. (2019) (9)
Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases (2019) (8)
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis. (2021) (8)
Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease (2021) (8)
Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria (2010) (8)
Overexpression of leptin mRNA in the mesenteric adipose tissue of inflammatory bowel disease (IBD) (2000) (8)
Are anti-saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (PANCA) useful in indeterminate colitis? A prospective follow-up study (2000) (8)
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes (2019) (8)
[Decrease of fecal beta-galactosidase activity in Crohn disease]. (1993) (8)
[Laser resection of a pedunculated giant lipoma of the esophagus]. (1992) (8)
Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis. (1995) (8)
Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy? (2008) (8)
CROHN'S DISEASE IN A MARRIED COUPLE AND THEIR FOUR CHILDREN (1989) (8)
Editorial: biologics in inflammatory bowel disease―time for direct comparisons (2017) (8)
Recycling of Pre-Colectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation is Associated with Treatment Failure. (2020) (8)
Understanding combination therapy with biologics and immunosuppressives for the treatment of Crohn's disease. (2010) (8)
Assessing patients’ satisfaction with anti-TNFα treatment in Crohn’s disease: qualitative steps of the development of a new questionnaire (2011) (8)
[Eosinophils and pathology of the digestive tract]. (1990) (8)
Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. (2020) (8)
Immunoglobulin G Subclass Distribution of Anti-Endothelial Cell Antibodies (AECA) in Patients with Ulcerative Colitis or Crohn's Disease (1997) (8)
Uric acid levels are independent of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease: A reappraisal of the role of S. cerevisiae in this setting (2018) (8)
Mortality and Rates of Graft Rejection or Failure Following Intestinal Transplantation in Patients With vs Without Crohn's Disease. (2016) (7)
Adverse Events During Anti-TNF&agr; Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies (2016) (7)
Serological aspects of coeliac disease. (1992) (7)
Anti-endothelial cell antibodies in sera from patients with inflammatory bowel disease. (1995) (7)
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials (2019) (7)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. (2021) (7)
Sustained Steroid-Free Clinical Remission in Patients with Moderate to Severe Crohnʼs Disease Treated with Adalimumab: 1181 (2006) (7)
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. (2009) (7)
DOP065 Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial (2018) (7)
Evolution of Endoscopic Activity Scores in Patients With Crohn's Disease Under Azathioprine and/or Infliximab: A Post-Hoc Analysis of the Sonic Data (2011) (7)
313 Long-Term Outcome After Infliximab Withdrawal for Sustained Remission in Crohn's Disease (2016) (7)
Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn’s Disease With Short Bowel Syndrome (2017) (7)
S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study (2020) (7)
A Users Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. (2019) (7)
496 Long-Term Safety of An Anti-TNF Drug By Duration of Exposure Compared to Non-Anti-TNF Exposed Patients with Crohn's Disease: Novel Data from the Certolizumab Pegol Development Program (2008) (7)
S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study (2010) (7)
W1096 Results from An Open-Label Extension of CHARM: Steroid-Free Remission in Patients with Crohn's Disease Who Received Adalimumab Therapy for At Least 3 Years (2009) (7)
Paraneoplastic intestinal pseudo-obstruction as the presenting feature of small-cell lung cancer. (1988) (7)
[Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders]. (1993) (7)
Inflammation affects sufentanil consumption in ulcerative colitis (2008) (7)
Ileocolic anastomotic inflammation after resection for Crohn’s disease indicates disease recurrence: a histopathologic study (2020) (7)
P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. (2017) (7)
277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (7)
Epidemiology of inflammatory bowel disease: is there a "Belgian-French exception?". (1996) (7)
Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series. (2020) (7)
DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis (2018) (7)
[Intestinal microflora and chronic inflammatory bowel diseases]. (2001) (6)
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (2018) (6)
P213 Influence of clinical history on scoring of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (6)
Sa1209 Factors Affecting Adalimumab Pharmacokinetics in Adult Patients With Moderate to Severe CD (2013) (6)
DOP032 Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American survey (2018) (6)
Erratum: Effects of adalimumab maintenance therapy on health-related quality of life of patients with crohn's disease: Patient-reported outcomes of the CHARM trial (American Journal of Gastroenterology (2008) 103 (3132-3141) DOI: 10.1111 / j.1572-0241.2008.02175.x) (2009) (6)
P554 Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial. (2017) (6)
CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. (2001) (6)
Corrigendum to “European-evidence-based consensus on the management of ulcerative colitis: Current management” [J Crohns & Colitis 2 (2008) 24–62] (2008) (6)
Induction, Maintenance, and Sustainability of the Healing of Draining Fistulas in Patients with Crohnʼs Disease Treated with Adalimumab: Results of the CHARM Study (2006) (6)
Panel of serologic antibodies in patients with indeterminate colitis (2003) (6)
Targeting the Preclinical Phase of Inflammatory Bowel Disease. (2015) (6)
775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study (2021) (6)
New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry (2021) (6)
Constrictive and Hypertrophic Strictures in Ileal Crohn's Disease. (2021) (6)
Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist (2012) (6)
Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm (2019) (6)
[Collagenous gastritis, duodenitis, ileitis and colitis]. (2001) (6)
Activated eosinophils in coeliac disease. (1990) (6)
α-chain disease: Analysis of α-chain protein and secretory component in jejunal fluid (1993) (6)
Prevalence and progression of incidental terminal ileitis on non-diagnostic colonoscopy: a systematic review and meta-analysis. (2021) (6)
865 Phase IIB, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Ulcerative Colitis (2014) (6)
Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD) (1998) (6)
Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohnʼs Disease Treated with Vedolizumab: 1676 (2013) (6)
Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2: 984 (2007) (6)
856 Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial (2016) (6)
[Chronic pancreatitis: an extraintestinal manifestation of hemorrhagic rectocolitis?]. (1997) (6)
P0720 INCIDENCE AND PRESENTATION OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) AT DIAGNOSIS. A PROSPECTIVE POPULATION-BASED STUDY IN NORTHERN FRANCE (1988???1999) (2004) (6)
Evidence for Life Before Inflammatory Bowel Disease. (2016) (6)
Fine mapping of the inflammatory bowel disease susceptibility locus 1 (IBD1) in the pericentromeric region of chromosome 16 (1998) (5)
Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients: The ACT Trials (2005) (5)
Granulomatous pancreatitis: Crohn's disease or sarcoidosis? (1996) (5)
Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post hoc Analysis: 670 (2017) (5)
T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) (2008) (5)
P137 Long-term outcome of paediatric-onset Crohn's disease: A population-based study (2012) (5)
Endoscopic fluorescence imaging for the study of anastomotic recurrences in Crohn's disease (CD) correlation with histological findings (1999) (5)
Sustainability of Adalimumab in Fistula Healing and Response: 2-Year Data from CHARM and 12-Month Open-Label Extension Follow-Up Study: 1034 (2007) (5)
Mo1794 Delayed Response to Golimumab Therapy: UC Patient Characteristics and Long-term Clinical Outcome: Post-Hoc Analyses from the PURSUIT Program (2016) (5)
Ustekinumab Dose Intensification Can Be Effective in Crohnʼs Disease Patients Not Responding to Induction (2018) (5)
Azathioprine (AZA) for ulcerative coltis: A retrospective multicente study on 131 patients (2001) (5)
Immune Cell Therapy in IBD (2014) (5)
Tu1724 – Association of Ustekinumab Serum Concentrations and Perianal Fistula Resolution in the Crohn's Disease Uniti Program (2019) (5)
Date of birth in familial Crohn's disease suggests environmental factors (1998) (5)
Endoscopic ultrasonography in the diagnosis of hypertrophic gastropathy. (1994) (5)
Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P-21 (2012) (5)
Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn’s Disease: A Gemini 2 Post hoc Analysis (2017) (5)
387 A Placebo-Controlled Trial of Visilizumab in Patients with Intravenous (IV) Steroid Refractory Ulcerative Colitis (UC) (2009) (5)
P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (5)
Comment on ‘Anti-Adhesion Therapies and the Rule of 3 for Rare Events’ (2014) (5)
P020 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease after Failure of Two Other Anti-TNF (2008) (5)
Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years (2018) (5)
Periperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease (2003) (5)
The importance of familial clusterings in Crohn's disease. (2001) (5)
Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies: 1716 (2013) (5)
Sa1842 – Delayed Diagnosis of Crohn’s Disease is Common and Associated with an Increased Risk of Disease Complications (2019) (5)
6 Development of the Crohn's disease (CD) digestive damage score: the Lémann score (2013) (5)
[Gastric metastasis of a malignant melanoma of the choroid]. (1984) (5)
Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (2013) (5)
[Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy]. (1991) (5)
922 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease Through 2 Years (2008) (5)
Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. (2021) (5)
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability. (2021) (5)
When should combination therapy for patients with Crohn's disease be discontinued? (2012) (5)
Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States (2020) (5)
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. (2018) (5)
OP009 Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial. (2017) (5)
Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohnʼs Disease and in Those with Prior Infliximab Exposure: Results from an Open-Label Extension Study (2006) (5)
NATURAL HISTORY OF CROHN'S DISEASE IN CHILDREN: A POPULATION-BASED COHORT STUDY IN NORTHERN FRANCE (2006) (5)
Adalimumab Safety in Crohnʼs Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials: 1031 (2007) (5)
DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM (2018) (4)
Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids: A Systematic Review and Meta-Analysis: 1772 (2014) (4)
[Digestive lymphomatous polyposis]. (1992) (4)
Sa1151 Intestinal Transplantation for Crohn's Disease: A 5-Year Nationwide Follow-Up (2015) (4)
Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years (2017) (4)
Sa1204 Deep Remission As a Predictor of Clinical Outcomes in Vedolizumab-Treated Patients With Ulcerative Colitis (2015) (4)
Age Is Just a Number—Frailty Associates With Outcomes of Patients With Inflammatory Bowel Disease (2020) (4)
Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: 1524 (2012) (4)
MUTATION SCREENING IN THE CD19 AND CD43 (SIALOPHORIN) GENES IN CROHN DISEASE PATIENTS (1999) (4)
[Celiac disease in adults: new aspects]. (2004) (4)
[Acute pancreatitis associated with corticosteroid treatment in Crohn's disease]. (2003) (4)
Effect of disease duration on 'deep remission': Results from the EXTEND trial (2010) (4)
[Familial occurrence of collagenous colitis]. (2005) (4)
Tu1381 Genome-Wide Association Identifies Multiple Collagenous Colitis Susceptibility Loci (2014) (4)
Vedolizumab Induction Therapy for Patients With Crohn’s Disease and Prior Anti‐TNF Antagonist Failure: A Randomized, Placebo‐controlled, Double‐blind, Multicenter Trial: P‐26 (2012) (4)
The CHARM Trial of Adalimumab in Crohn's Disease. (2006) (4)
Sa1203 Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies (2013) (4)
A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY (2018) (4)
P008 - Adalimumab sustains quality-of-life improvements in patients with Crohn's disease: 3-year data from CHARM (2009) (4)
[Epidemiology and risk factors of inflammatory bowel diseases]. (2005) (4)
Pure red cell aplasia during the course of virus A hepatitis. (1990) (4)
Anti-TNF Withdrawal in Inflammatory Bowel Disease (2016) (4)
105 Natural History of Ulcerative Colitis in the Elderly: A Population-Based Study (2012) (4)
International Differences in Gastroenterologists' Perspective on Stopping Therapy for Patients with Crohn's Disease (2017) (4)
IBD therapy: new targets and unmet needs. (2014) (4)
Management of Crohn's disease (CD) of the ileoanal pouch with infixinab (2003) (4)
[Diffuse jejuno-ileitis of Crohn's disease: a separate form of the disease?]. (1999) (4)
Endoscopic Mucosal Improvement in Patients with Active Crohnʼs Disease Treated with Certolizumab Pegol: First Results of the Music Clinical Trial (2008) (4)
P002 Adalimumab Maintains Long-Term Remission in Crohn's Disease through 2 Years (2008) (4)
T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial (2008) (4)
Sa1066 Cost Effectiveness Analysis of Fecal Microbiota Transplant and Antibiotic Treatment for Recurrent Clostridium difficile Infection (2014) (4)
COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions (2020) (4)
105 Natural History of Crohn's Disease in the Elderly: A Population-Based Study (2012) (4)
Association of Steroid-Free Clinical Remission and Complete Mucosal Healing at 6 Months With Clinical Outcome at 1 Year: A Post-Hoc Analysis of SONIC trial Data (2011) (4)
S1065 Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data (2009) (4)
90 Safety and Efficacy of Laquinimod in Inducing Clinical and Biochemical Improvement in Active Crohn's Disease: Results of an Exploratory Trial (2013) (4)
796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study (2019) (4)
OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM (2018) (4)
1049 Identification of Items to Be Included in An Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2009) (4)
P052 Risk Factors For Initial Surgery in Pediatric Patients with Crohn's Disease: A Population-Based Cohort Study (2007) (4)
Safety of Vedolizumab Alone or With Concomitant Corticosteroids and/or Immunosuppressants in Patients With Ulcerative Colitis or Crohn’s Disease: 1617 (2014) (4)
Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1 (2020) (4)
Cluster of Crohn's disease in Herny, France, including 2 cases from a common residence. (2007) (4)
Mo1223 Health-Related Quality of Life in Patients With Ulcerative Colitis After Treatment With Vedolizumab: Results From the Gemini 1 Study (2014) (4)
Outcomes of Passable and Non-Passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. (2021) (4)
[Intestinal ulceration in celiac disease in the adult. Value of peroperative enteroscopy]. (1989) (4)
PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium (2017) (4)
M2003 Low Inter-Observer Agreement on Nodular Regenerative Hyperplasia of the Liver: An European Inter-Observer Analysis (2010) (4)
Measuring patients’ satisfaction with their anti-TNF treatment in severe Crohn’s disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn’s diseasE Questionnaire (SPACE-Q©) (2014) (4)
Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension. (2021) (4)
102 Clinical and Phenotypic Characteristics of Ulcerative Colitis at Diagnosis According to Age: A Population-Based Study (2012) (4)
[Relevance of anti-tissue transglutaminase antibodies in coeliac disease diagnosis]. (2003) (4)
[Intestinal surgery in the treatment of stenoses of the small intestine in Crohn disease]. (1994) (4)
A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Candida Yeasts and Fluconazole in Crohn’s Disease (2021) (4)
Alpha-chain disease: analysis of alpha-chain protein and secretory component in jejunal fluid. (1993) (3)
Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study: 1709 (2014) (3)
[Role of the digestive tract immune system in the control of bacterial translocation in gnotoxenic mice]. (1986) (3)
[A diffuse form of canalicular ectasia of pancreas?]. (1988) (3)
Identification of volumetric laser endomicroscopy features of colon polyps with histologic correlation. (2018) (3)
Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti‐TNF medications (2018) (3)
Effects of Infliximab Therapy on Transmural Lesions Assessed by MRI Enteroclysis in Patients With Ileal Crohn's Disease: The ACTIF Study (2011) (3)
Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies: P‐30 (2012) (3)
Infants Born to Mothers with Inflammatory Bowel Disease Exhibit Distinct Microbiome Features that Persist Up to 3 Months of Life (2017) (3)
Endoscopic Improvement in Patients with Active Crohnʼs Disease Treated with Certolizumab Pegol: Results of Blinded Central Reading of Recorded Endoscopies from the MUSIC Study (NCT00297648): 1154 (2010) (3)
Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease (2017) (3)
Predictors of the need for second intestinal resection in children with Crohnʼs disease: O-12. (2011) (3)
Age is Just a Number: How Frailty May Predict Outcomes Within Inflammatory Bowel Disease. (2020) (3)
Su1913 - Crohn's Disease Patients' Perspectives Towards De-Escalating Immunosuppressive Therapy: A Comparative French and American Survey (2018) (3)
Activation of PPARΓ protects against colon inflammation by inhibiting TNFA signaling pathways (2000) (3)
Achievement of Early Deep Remission Is Associated with Lower Rates of Weekly Dosing for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND: 1208 (2010) (3)
Deciphering the combinatorial influence of diet and the microbiota on experimental colitis (2017) (3)
141 Pregnancy Outcome in Inflammatory Bowel Disease for Women Treated with Thiopurine: Cohort from the CESAME Study (2009) (3)
A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. (2010) (3)
Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately‐to‐Severely Active Ulcerative Colitis: ULTRA 2 Subanalysis: P‐22 (2012) (3)
Un cas de gastrite lymphocytaire exsudative traitée par oméprazole (1990) (3)
Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (3)
Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo (2011) (3)
Triple infection fongique chez un patient avec cirrhose hépatique (2012) (3)
PWE-254 Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease (2012) (3)
DOP094 Cancer in elderly-onset inflammatory bowel disease: A population-based study (2014) (3)
TPQL3: QUALITY OF LIFE IN CROHN DISEASE: A PROSPECTIVE, LONGITUDINAL STUDY IN 231 PATIENTS (1999) (3)
Mo1832 - Baseline Level of Integrin A4B7 on Circulating Plasmablasts Predicts Response to Vedolizumab in Patients with Inflammatory Bowel Disease (2018) (3)
Luminal narrowing alone allows an accurate diagnosis of Crohn's disease small bowel strictures at cross-sectional imaging. (2020) (3)
Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families. (2020) (3)
W1092 Maintenance of Long-Term Remission in Patients with Moderately to Severely Active Crohn's Disease Treated for 3 Years with Adalimumab: Results from the Open-Label ADHERE Study (2009) (3)
Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease: 1025 (2007) (3)
Integrated Care for Crohn’s Disease: A Plea for the Development of Clinical Decision Support Systems (2018) (3)
Autologous Cellular Therapy Open Label Phase I Study in Crohn's Disease With Type 1 Regulatory (Tr1) Lymphocytes (CATS1) (2011) (3)
Impact of Adalimumab (HUMIRA®) on Patient‐Reported Outcomes among Patients with Fistulizing Crohn's Disease in the CHARM Trial: 921 (2007) (3)
Stratification of Crohn's disease by anti Saccharomyces cerevisiae mannan antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA) (1998) (3)
P053 TARGETED RELEASE ORAL CYCLOSPORINE FORMULATION AS A POTENTIAL NEW THERAPY FOR ULCERATIVE COLITIS (2019) (3)
17 - Improved Quality of Care and Quality of Life for IBD Patients using Healthpromise App: A Randomized, Control Trial (2018) (3)
Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials (2019) (3)
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States (2021) (3)
Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study (2018) (3)
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations. (2021) (3)
Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium: 1904 (2015) (3)
Are anti-endomysial (AEM) and anti-transglutaminase (TTG) antibodies reliable markers of strict diet compliance in adult celiacs on a gluten free diet (GFD)? (2000) (3)
Disability in Inflammatory Bowel Disease (IBD): Developing Icf Core Sets for Patients With IBD Based on the WHO International Classification of Functioning, Disability and Health (2011) (3)
DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis. (2017) (3)
P697 Candida albicans colonization and anti-glycan antibodies in active and quiescent Crohn's disease (2013) (3)
Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease. (1989) (3)
OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301). (2017) (3)
Sustained Clinical Remission of Ulcerative Colitis is Associated with Greater Improvements in Quality of Life, Work Productivity and Activity: 1210 (2011) (3)
Evidence for Chlamydia in Crohns Disease (2016) (3)
OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1 (2016) (3)
Mucosal Healing in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P‐20 (2012) (3)
P568 Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2 (2013) (3)
Identification of Subgroups of Adalimumab-Treated Patients With Crohn's Disease Who Experience High Rates of Deep Remission (2011) (3)
Evidence for Chlamydia in Crohn’s Disease (2016) (3)
Impact of Real World Home-Based Remote Monitoring on Quality of Care and Quality of Life in IBD Patients: Interim Results of Pragmatic Randomized Trial (2017) (3)
Quantification of discrete gut bacterial strains following fecal transplantation for recurrent Clostridioides difficile infection demonstrates long-term stable engraftment in non-relapsing recipients (2020) (3)
[Triple fungal infection in a patient with liver cirrhosis]. (2012) (3)
Comparative Colorectal Cancer Risk in Patients with Ulcerative Colitis Treated with Adalimumab Versus Conventional Therapy: 1598 (2012) (3)
[Celiac disease and liver involvement]. (2003) (3)
[Optical coherence computed tomography in gastroenterology]. (2005) (3)
Sa1931 The Impact of Bariatric Surgery on the Course of Inflammatory Bowel Disease (2016) (3)
Withdrawal of drug therapy for patients with quiescent Crohn's disease (2017) (3)
DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. (2017) (3)
Su1289 Development of Red Flags for Early Referral of Adults With Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative (2014) (3)
P160 Faecal Lactoferrin is a reliable IBD biomarker during pregnancy (2018) (3)
Early Surgery is Not Associated With Poor Prognosis in Pediatric Crohn's Disease: A Population-Based Study (2011) (3)
Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home (2021) (3)
A147 RESPONSE AND REMISSION AFTER 16 WEEKS OF USTEKINUMAB– AN ALL PATIENTS ANALYSIS FROM THE UNITI CROHN’S STUDIES (2018) (3)
Splenic abscess associated with Pasteurella multocida in an immunocompetent patient. (1995) (3)
44 Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study) (2010) (3)
P386 Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease (2014) (3)
557 Cancer in Elderly-Onset Inflammatory Bowel Disease: A Population-Based Study (2014) (3)
AGA AbstractsW1244 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease After Failure of Two Other Anti-TNF (2008) (3)
Mo1867 - Shorter Disease Duration is Associated with Higher Response Rates to Vedolizumab in Crohn's Disease but not Ulcerative Colitis: A Multi-Center Consortium Analysis (2018) (2)
128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS (2021) (2)
[Bacterial translocation of endogenous bacteria]. (1995) (2)
Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug? (2019) (2)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance: 1665 (2012) (2)
P-135 A Description of Joint-Related Events in Patients Receiving Vedolizumab from Clinical and Post-marketing Safety Experience (2017) (2)
Risk of Squamous and Basal Cell Carcinomas in Patients With Inflammatory Bowel Disorders Exposed to Thiopurines: The CESAME National Cohort Study (2011) (2)
P019 Subcutaneous Certolizumab Pegol is Effective in Patients With Prior Infliximab Exposure, or Concomitant Immunosuppressant or Glucocorticoid Treatment: Data From Precise 2 (2007) (2)
Early and Sustained Remission after Treatment with Subcutaneously Administered Golimumab Is Associated with Normalized Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Post-hoc Analysis from PURSUIT Induction and Maintenance Trials: 1721 (2013) (2)
New Blood Marker of Endoscopic Disease Activity—A Step Forward in Treating Crohn’s Disease to Target? (2020) (2)
Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium (2016) (2)
Mo1687 Efficacy of Anti-TNF on Severe Postoperative Endoscopic Recurrence in Crohn's Disease (2012) (2)
Diet Modifies Colonic Microbiota and CD4+ T Cell Repertoire to Trigger Flares in a Novel Model of Colitis Induced by IL-23 (2018) (2)
Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study Data (2014) (2)
Mo1357 Long-Term Outcome of Paediatric-Onset Ulcerative Colitis: Early Years Are Shaping the Future (2013) (2)
328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (2)
Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
P493 Factors affecting adalimumab pharmacokinetics in adult patients with moderate to severe CD (2013) (2)
Long‐Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: P‐19 (2012) (2)
Crohn's Disease Associated Dysbiosis as a Predictive Factor of Clinical Relapse: A Microbiological Substudy of the GETAID-STORI Cohort (2011) (2)
Management of Severe Ulcerative Colitis (2015) (2)
Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified? (2006) (2)
P139 INSIGHTS INTO PATIENT AND PHYSICIAN COMMUNICATION AND EXPECTATIONS: RESULTS OF A LARGE PAN-EUROPEAN SURVEY OF PHYSICIANS AND THEIR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2008) (2)
[Cholesterol embolism: unusual cause of small intestine occlusion]. (2000) (2)
[Sarcoidosis and the digestive tract]. (1994) (2)
[Eosinophilic pancreatitis: a difficult diagnosis]. (1998) (2)
P005 DELAY IN DIAGNOSIS OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (2)
Mo1882 The Efficacy of Vedolizumab by Disease Activity and Prior Tumor Necrosis Factor α Antagonist Failure in Patients With Ulcerative Colitis or Crohn's Disease: Post Hoc Analyses From the GEMINI 1 and GEMINI 2 Studies (2016) (2)
Conjugal forms of inflammatory bowel diseases (IBD) in Northwestern France and Belgium: More than expected by chance (1999) (2)
835 – Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results from the Gemini Lts Study (2019) (2)
P705 Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease. (2017) (2)
Microbial-Host Interactions in Inflammatory Bowel Disease, Functional Bowel Disease, Obesity and Obesity-Related Metabolic Disease. (2018) (2)
CX601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells (EASC), for Complex Perianal Fistulas in Crohn's Disease: Long-Term Results from a Phase III Randomized Controlled Trial (2017) (2)
797 – Real-World Safety of Tofacitinib in Inflammatory Bowel Diseases: A Multi-Center Study (2019) (2)
P083 - Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM (2009) (2)
Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohn's Disease: Subanalysis of CHARM: 922 (2007) (2)
P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SC (2013) (2)
DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis (2018) (2)
[Ultrasound endoscopic aspect of lymphocytic gastritis]. (1993) (2)
Su450 EFFECTIVENESS AND SAFETY OF COMBINING BIOLOGICS AND/OR SMALL MOLECULES IN INFLAMMATORY BOWEL DISEASES: SYSTEMATIC REVIEW WITH META-ANALYSIS (2021) (2)
Health-related quality of life improvements in patients with active crohn's disease following treatment with certolizumab pegol in the MUSIC Study (NCT00297648). (2011) (2)
OP17 A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies (2019) (2)
S1063 Sustained Improvement in Quality of Life for Patients with Fistulizing Crohn's Disease Treated with Adalimumab: 3-Year Data from CHARM (2009) (2)
Sa1759 - Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data Adjusting for Both Induction and Remission Phases and Prior Exposure to TNF Antagonists (2018) (2)
Sa1139 Safety of Certolizumab Pegol in 2570 Crohn's Disease Patients With 4378 Patients Years at Risk: Integrated Data From the Global Clinical Program (2015) (2)
PTU-109 Efficacy and safety of adalimumab in moderate compared with severe Crohn's disease: pooled data from the charm and extend trials (2012) (2)
Sa1761 AN INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH INCREASED CLINICAL REMISSION RATES AND LOWER STEROID USE (2020) (2)
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease (2021) (2)
[Fluorescent imaging in digestive endoscopy]. (2006) (2)
Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months (2021) (2)
DOP099 Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn's disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab (2014) (2)
P113 Short-Term Adalimumab Therapy Improves Quality of Life in Patients Who had Failed Infliximab Therapy: Results From the Gain Trial (2007) (2)
ASCA (anti-saccharomyces cerevisiae antibodies) in healthy relatives of sporadic and familial Crohn's disease patients (2001) (2)
Certolizumab Pegol Is Efficacious in Crohnʼs Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure: 1103 (2008) (2)
P019 LONG-TERM FISTULA HEALING AND RESPONSE WITH ADALIMUMAB TREATMENT: 2-YEAR DATA FROM CHARM INCLUDING 1-YEAR OPEN-LABEL EXTENSION (2008) (2)
Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2 (2013) (2)
Sa1818 – Innate Immune Dysregulation, Detectable Up to 6 Years Before the Diagnosis of Crohn's Disease, is Significantly Amplified in Patients with a Complicated Phenotype (2019) (2)
258 Validation of Simplified Stricture Severity Score (4S) to Predict the Need for Surgery in Patients With Stricturing Crohn's Disease (2014) (2)
S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study (2020) (2)
Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
Sa473 RISK PROFILING OF UNAFFECTED MEMBERS OF FAMILIES WITH A HISTORY OF IBD USING SEROLOGY SCORE, DYSBIOSIS SCORE, POLYGENIC RISK SCORE, AND FECAL CALPROTECTIN (2021) (2)
Sa1138 Patients With Inflammatory Bowel Disease and a History of Cancer: The Risk of Cancer Following Exposure to Immunosuppression (2015) (2)
325 - Factors Driving Treatment Escalation in Crohn's Disease in the Calm Trial (2018) (2)
P043 Long-Term Steroid-Free Remission in Crohn's Patients Receiving Adalimumab: The Charm Trial (2008) (2)
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. (2016) (2)
PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohnʼs Disease: 694 (2017) (2)
DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis (2018) (2)
Sa1246 Clinical and Phenotypic Characteristics of Crohn's Disease in Elderly People: A Population-Based Study (2012) (2)
Environmental Risk Factors in Paediatric IBD (2006) (2)
Agreement between Crohn’s Disease Endoscopy Severity Scores Derived from Live Local, Delayed Local Video-Recorded and Central Readings (2017) (2)
P-016 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis (2016) (2)
Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium (2017) (2)
DOP015 International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's disease. (2017) (2)
A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in crohn disease (2003) (2)
Inflammatory Bowel Disease Therapy and Venous Thromboembolism (2020) (2)
Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately to Severely Active Ulcerative Colitis: Subanalysis of ULTRA 2: 1541 (2012) (2)
[Excluded rectum during Crohn's diseases: what is the risk of dysplasia?]. (1999) (2)
Inflammatory bowel disease microbiotas alter gut CD4 T-cell homeostasis and drive colitis in mice (2018) (2)
The value of anti-Saccharomyces cerevisiae antibodies (ASCA) as subclinical marker in Crohn's disease (CD) (1999) (2)
Su1882 - Post-Inflammatory Polyps do not Predict Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: A Multinational Retrospective Cohort Study (2018) (2)
Small-bowel ulcerations at wireless capsule endoscopy: go the whole way (2007) (2)
[Transient ischemic colitis complicating sickle cell crisis]. (1991) (2)
Escherichia coli strain nissie 1917 inhibits adhesion to an invasion of intestinal epithelial cells by adherent-invasive E. colil isolated from a Crohn's disease patient (2001) (2)
A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohnʼs Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598 (2017) (2)
Su1745 Characterization of Molecular Response to Golimumab in Ulcerative Colitis by mRNA Expression Profiling: Results From Pursuit-SC Induction Study (2013) (2)
P124 Sustainability of Adalimumab in Improving the Quality of Life of Patients with Fistulizing Crohn's Disease: 2-Year Data from Charm (2008) (2)
Su1220 Rectal Bleeding Accurately Reflects Level of Mucosal Inflammation in Patients With Ulcerative Colitis (2015) (2)
Molecular form of faecal alpha 1 antitrypsin in patients with Crohn's disease. (1992) (2)
P692 Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review (2018) (2)
DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial (2018) (2)
Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm (2018) (2)
S1232 The TOUCH™ Program and Risk Management Plan for the Administration of Natalizumab: Lessons and Updated Safety Results from the Use of Natalizumab in Patients with Relapsing Multiple Sclerosis and Implications for Potential Use in Crohn's Disease (2008) (2)
OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension (2014) (2)
P078 ADALIMUMAB SUSTAINS QUALITY-OF-LIFE IMPROVEMENTS IN PATIENTS WITH CROHN'S DISEASE: 2-YEAR DATA FROM CHARM (2008) (2)
Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT‐SC Induction: P‐69 (2012) (2)
IBD and IBS: novel mechanisms and future practice. Preface. (2009) (2)
Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice (2016) (2)
Mo1246 Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Study (2014) (2)
Su1237 Evolution of the Lemann Index in Crohn's Disease: A Retrospective Study (2015) (2)
93 Clinical and Endocopic Improvement Following Hemopoietic Stem Cell Transplantation vs Mobilisation Alone in Crohn's Disease (2013) (2)
[Treatment with interferon alpha and plasma exchange of periarteritis nodosa associated with acute viral hepatitis B]. (1993) (2)
[Etiology of Crohn disease. Current data]. (1994) (2)
103 Long-Term Outcome of Paediatric-Onset Crohn's Disease: A Population-Based Study (2012) (2)
OP05 Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease (2012) (2)
P257 Importance of deep remission compared with mucosal healing only: Results from EXTEND (2012) (2)
P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial (2018) (2)
Early ileal lesions of Crohn's disease (CD) are associated with the expression of IL-4 and IgE and not of inflammatory cytokines (1998) (2)
P018 Certolizumab Pegol is Effective in Patients Regardless of CRP Level And Disease Duration: Data From Precise 2 (2007) (2)
16 Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's disease: analyses from the SONIC trial (2013) (2)
Mo1844 – Long-Term Fate of the Excluded Rectum in Crohn’s Disease (2019) (2)
114 The Changing Pattern of Crohn's Disease Incidence According to Age in Northern France: A Constant Increase in the 0-19 Year's Age Group (1988-2005) (2009) (2)
Clinical Value of Measuring Trough Levels and Human Anti-Chimeric Antibodies in Patients With Inflammatory Bowel Disease Who Lost Response to Infliximab Therapy (2011) (2)
[Chronic myelomonocytic leukemia and Crohn disease]. (1995) (2)
P394 Rate of and response to dose escalation in patients treated with adalimumab for moderately to severely active ulcerative colitis: subanalysis of ULTRA 2 (2013) (2)
Spontaneous intrahepatic hematoma revealing nodular periarteritis. (2004) (2)
Refractory spure: Histological and phenotypical features and outcome (1998) (2)
P225 Impact of subcutaneously administered golimumab on disease specific and generic health-related quality of life in patients with moderately to severely active ulcerative colitis: Results from PURSUIT-SC induction (2013) (2)
Clinical disease activity in the CALM study – Authors' reply (2018) (2)
P321 Recurrence of Crohn's disease after definitive stoma: A retrospective study in 83 patients (2012) (2)
Mesalamine(M) in Crohn's disease (CD) patients with prednisolone-induced remission: Effect on steroid weaning and remission maintenance in the year after weaning: A placebo-controlled, multicentre double-blind trial (1995) (2)
P875 Faecal calprotectin (FC) in babies born to mothers with or without IBD and correlation with microbiome (2018) (2)
A Simple Method for the Measurement of Different Forms of α1 Proteinase Inhibitor in the Faeces of Patients with Crohn's Disease (1992) (2)
[Antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae mannan antibodies: new biological tools for diagnosis of inflammatory bowel disease]. (2003) (1)
P453 Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis (2018) (1)
[Pseudotumor nodular lymphoid hyperplasia of the ileum]. (1997) (1)
P154 - Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis of controlled trials with individual patient data (2009) (1)
P363 Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes (2018) (1)
T2027 Lactobacillus casei Dn-114 Oo1 Strain in the Prevention of Postoperative Recurrence of Crohn's Disease: A Randomised, Double-Blind Placebo-Controlled Trial (2010) (1)
The CARD 8 p . C 10 X mutation associates with a low anti-glycans antibody response in patients with Crohn ’ s disease (2013) (1)
Su1084 Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease (2014) (1)
Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice (2016) (1)
article : infliximab for Crohn ’ s disease treatment – shifting therapeutic strategies after 10 years of clinical experience (2011) (1)
Tu1899 REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB IN CROHN'S DISEASE: A MULTI-CENTER STUDY (2020) (1)
T1141 Co-Administration of Certolizumab Pegol with Immunosuppressants and/or Corticosteroids Is Not Associated with An Increased Risk of Adverse Events with Crohn's Disease: Analysis of Pooled Data (2008) (1)
P213 Benefit risk assessment of adalimumab as maintenance treatment for ulcerative colitis: Near analysis of week 8 responders in ULTRA 2 (2012) (1)
OP009 A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study (2018) (1)
Lymphoma and IBD: What is the Actual Risk? (2011) (1)
P360 Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity (2019) (1)
P733 Past history of bariatric surgery associated with increased risk of new onset inflammatory bowel disease. (2017) (1)
[Transhepatic embolization and endoscopic sclerosing in digestive hemorrhage caused by rupture of esophageal varices in patients with Child's stage C cirrhosis]. (1990) (1)
T1138 Global Safety of Adalimumab in Crohn's Disease Clinical Trials (2008) (1)
Mo1883 Response and Remission Rates With up to 3 Years of Vedolizumab Treatment in Patients with Ulcerative Colitis (2016) (1)
Value in capsule retention in Crohn's disease. (2011) (1)
[Interactions between gastrointestinal epithelial cells and immune system cells]. (1990) (1)
Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease: Results of the CHARM Trial (2006) (1)
Poster PresentationsP060 CORTICOSTEROIDS POSE AN INCREASED RISK FOR SERIOUS INFECTION: AN INTERIM SAFETY ANALYSIS OF THE ENCORE REGISTRY (2008) (1)
A767 ERYTHROCYTE SEDIMENTATION RATE AND OPIOID REQUIREMENT IN CROHN'S DISEASE (1997) (1)
P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy (2009) (1)
Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease (2015) (1)
[Indications of surgical treatment of Crohn disease]. (1993) (1)
[Dihydralazine hepatitis]. (1985) (1)
Skipping Crohn's disease: when ileocolonoscopy is not enough. (2012) (1)
Surgery is associated with fluctuations in ASCA levels suggesting antigenic stimulation (2000) (1)
Mucosal Healing Is Associated With Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis Presidential Poster: 1953 (2015) (1)
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply (2020) (1)
OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry (2021) (1)
: influenza A ( H 1 N 1 ) virus in patients with inflammatory bowel disease (2009) (1)
P126 Post-inflammatory polyps do not predict colorectal neoplasia in patients with inflammatory bowel disease: a multinational retrospective cohort study (2018) (1)
Mycophenolate mofetil (MMF) in refractory Crohn's disease after failure of treatments by azathioprine (AZA) or methotrexate (MTX) (2008) (1)
P243 Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates for adalimumab-treated patients with early Crohn's disease (2012) (1)
M1949 Are Small Bowel Adenocarcinoma (SBA) Complicating Crohn's Disease (CD) Associated With Dysplasia? (2010) (1)
Immunogenicity of Natalizumab in Crohnʼs Disease Following Continuous or Interrupted Dosing: 1143 (2006) (1)
EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY: 831 (2004) (1)
Abdominal radiotherapy: does it cause pancreatic carcinoma? (1994) (1)
Natalizumab: a promising treatment for Crohn’s disease (2006) (1)
P057 Development of a New Optimized 5-ASA Molecule GED-0507-34 with Intestinal Anti-Inflammatory and Analgesic Properties (2008) (1)
Sa1836 FRAILTY AS A RISK FACTOR FOR HOSPITAL READMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE STUDY (2020) (1)
Antibiotics: Which, When, and For How Long? (2007) (1)
Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohn’s Disease Treated with Mongersen (GED-0301) (2017) (1)
P071 Risk Factors Associated With Small Bowel Adenocarcinoma in Crohn's Disease: A Case-Control Study (2007) (1)
Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis (2014) (1)
L’exploration de l’intestin grêle par la video-capsule (VC): examen de 1ère intention pour le diagnostic de l’atteinte digestive de la réaction du greffon contre l’hôte (GI-GVHD)? (2004) (1)
Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD) (1998) (1)
Fecal alpha 1-antichymotrypsin in inflammatory bowel diseases. (1990) (1)
P756 Assessment of metal exposures in deciduous teeth of patients with inflammatory bowel disease (2019) (1)
Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial (2009) (1)
S2008 Long- Term Outcome of Treatment With Infliximab in Paediatric Crohn's Disease:a Population-Based Study (2010) (1)
Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out. (2020) (1)
Long-Term Safety of Certolizumab Pegol in Crohnʼs Disease: Integrated Safety Findings on Serious Adverse Events of Special Interest (2008) (1)
Sa1202 Relationships Between Clinical Remission, C-Reactive Protein Normalization and Mucosal Healing in Crohn's Disease: Analyses From the SONIC trial (2013) (1)
Colonic Pseudopolyps Resulting in Iron Deficiency Anemia. (2017) (1)
Natalizumab Provides Consistent Induction Efficacy for Patients with Moderate to Severe Crohnʼs Disease and Elevated C-Reactive Protein: A Comparison of ENACT-1 and ENCORE (2006) (1)
Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment: O-033. (2008) (1)
Tu1744 – Targeted Release Oral Cyclosporine (ST-0529) As a Potential New Therapy for Ulcerative Colitis: Phase I Study Results (2019) (1)
945 HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY (2020) (1)
560 Crohn's Disease-Associated Adherent-Invasive Escherichia coli Target Peyer's Patches via Long Polar Fimbriae (2010) (1)
98 – Hormone Therapy for Cancer is a Risk Factor for IBD Progression (2019) (1)
Su1976 THE PREVALENCE OF INCIDENTAL TERMINAL ILEITIS IN PERSONS UNDERGOING NON-DIAGNOSTIC COLONOSCOPY: A META-ANALYSIS (2020) (1)
Opposite evolution of Crohn's disease an ulcerative colitis in northern France (1988–99) (2003) (1)
Diagnostic accuracy of patient‐reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis (2021) (1)
Su2085 Association of Baseline C-Reactive Protein With Maintenance of Remission in Anti-TNF-Experienced Patients With Moderate to Severe Crohn's Disease Treated With Adalimumab (2012) (1)
PUBLICATION TRENDS IN GASTROENTEROLOGY AND HEPATOLOGY OVER THE PAST 40 YEARS: AN ARTIFICIAL INTELLIGENCE ANALYSIS (2020) (1)
Su1243 Evaluation and Long-Term Benefit of Mucosal Healing in Crohn's Disease Patients Treated With Infliximab (2015) (1)
PTH-091 Effects of vedolizumab on HRQoL and work productivity in Crohn’s disease: results from versify (2019) (1)
PGI4 Health-Related Quality of Life Improvements in Patients with Active Crohn's Disease Following Treatment with Certolizumab Pegol in the Music Study (NCT00297648) (2011) (1)
S1186 Incidence of Microscopic Colitis in Northern France (2010) (1)
[An enigmatic occlusive syndrome]. (1988) (1)
P056 - Autologous Stem Cell Transplantation For Crohn's disease (ASTIC) trial: early report of toxicity and efficacy (2009) (1)
P412 Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis (2013) (1)
Early Involvement of Liver Natural Killer T Cells in Limiting Colonic Inflammation and Application to Disease Treatment (2011) (1)
Characterization of Mucosal Healing With Adalimumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease From EXTEND: 1611 (2014) (1)
S0798 Long-Term Outcomes of the Excluded Rectum in Crohn’s Disease – Results From the CAPER (Consortium to Assess Prognosis of the Excluded Rectum) Study (2020) (1)
Mo1696 Treatment With P28GST, a Recombinant Enzyme From Schistosome Helminth Parasite Prevents Hapten-Induced Colitis by Inducing a Regulatory Th2 Response (2014) (1)
Certolizumab Pegol Plasma Concentrations and Endoscopic and Clinical Outcomes in Crohnʼs Disease: A Post Hoc Analysis of the MUSIC Trial: Presidential Poster: 1667 (2012) (1)
Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND (2014) (1)
Su1925 Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease (2012) (1)
igh Prevalence of Adherent-Invasive Escherichia coli ssociated With Ileal Mucosa in Crohn ’ s Disease (1)
Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease (2011) (1)
PTU-110 Elevated C reactive protein in anti-TNF-naïve patients is associated with higher remission rates (2012) (1)
Risk of Malignancy, Infection, Serious Infection, and Acute Health Care Use in Patients With Crohnʼs Disease Treated With Adalimumab vs. Immunosuppressants: 1599 (2012) (1)
Su2083 One-Year Response and Remission Rates in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of Ultra 2 (2012) (1)
Mo1693 Mortality and Cancer in Paediatric Inflammatory Bowel Disease: A Population-Based Study (2012) (1)
P275 Clinical response is a meaningful endpoint in ulcerative colitis clinical studies (2013) (1)
S1056 Quality-of-Life Improvements in Patients with Crohn's Disease Treated for 3 Years with Adalimumab in An Open-Label Extension of CHARM (2009) (1)
334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis (2019) (1)
Mesenteric obesity in Crohn's disease (CD) (1998) (1)
Elevated C-reactive Protein in Anti-TNF-Naïve Patients is Associated with Higher Remission Rates: 1167 (2011) (1)
1080 Preclinical and Toxicological Assessments of the Novel Orally Bioavailable PPAR Ligand GED-0507-34-Levo for the Treatment of Inflammatory Bowel Disease (2010) (1)
131 SAFETY OF USTEKINUMAB IN IBD: A COMPREHENSIVE ANALYSIS OF MAJOR CARDIOVASCULAR EVENTS (MACE) THROUGH 5 YEARS IN CD AND 2 YEARS IN UC (2021) (1)
Factors Associated With Anxiety and Depression in IBD Patients: Results of the ISSEO Survey (2011) (1)
P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies (2018) (1)
Su1240 Comparison of Rectosigmoidoscopy and Colonoscopy for Assessment of Endoscopic Activity in Ulcerative Colitis (2015) (1)
Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn’s Disease: An Analysis of the PRECiSE 3 Study: 1722 (2014) (1)
Baseline C-reactive protein is associated with disease progression in patients with Crohnʼs disease: P-34. (2011) (1)
OP037 Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of life. (2017) (1)
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals (2018) (1)
Sa567 A COMPREHENSIVE INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION (2021) (1)
Tu1874 MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: UPDATED RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN (2020) (1)
P213 - Concurrence of inflammatory bowel disease and multiple sclerosis in general population: frequency, phenotypes and clinical course (2009) (1)
S02 Aluminum enhances inflammation and decreases healing in experimental models of colitis (2010) (1)
PTU-055 Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis (2013) (1)
Tu1337 Anti-TNFα Treatment Efficacy in Prevention of Postoperative Recurrence in Crohn's Disease Depends on Previous Exposure to Anti-TNFα Agents (2015) (1)
Confirmation of the importance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease (1998) (1)
Sustained Mucosal Healing in Adalimumab-Treated patients with moderate to severe Ileocolonic Crohnʼs Disease: Results of the EXTEND Trial: P-0028. (2009) (1)
High-dose Infliximab in Crohnʼs Disease: Clinical Experience, Safety, and Efficacy: 1675 (2013) (1)
P-005 YI Early Dose-escalation of Infliximab for Colectomy Avoidance in Anti-TNF Naïve UC Patients Hospitalized with Severe Colitis; A Tertiary-care Center's Experience (2013) (1)
[Intraductal biliary metastasis from colonic adenocarcinoma]. (1993) (1)
What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries (2021) (1)
Influence of genetics in the expression of serological markers in twins with IBD (2012) (1)
[Genetics of Crohn disease: a complex model]. (1996) (1)
OP019 In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study) (2018) (1)
Interpretation of Anti-TNF Drug Concentration and Antibody Levels in IBD: A Mobile App to Guide Management Based on Results From a RAND Appropriateness Panel: 1726 (2014) (1)
Effect of disease duration on ‘deep remission’ (2011) (1)
T1197 A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn's Disease (2008) (1)
Anticorps antiphospholipides et tube digestif (1996) (1)
Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P‐21 (2012) (1)
Su1846 SARCOPENIA PREDICTS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) OLDER THAN 50 YEARS STARTING BIOLOGIC MEDICATIONS (2020) (1)
Concomitant Use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis: P‐23 (2012) (1)
P214 - The changing pattern of Crohn's disease incidence according to age in Northern France: a constant increase in the 0 19 years age group (1988 2005) (2009) (1)
P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn's disease: a SONIC post hoc analysis. (2017) (1)
[Cytokines and anti-cytokines in chronic inflammatory intestinal diseases]. (1999) (1)
DOP033 Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND (2014) (1)
950 Addressing Unmet Needs of Inflammatory Bowel Disease Patients With Patient-Reported Outcomes App: A Mixed Methods Study (2015) (1)
Deglycosylation of alpha 1-proteinase inhibitor is impaired in the faeces of patients with active inflammatory bowel disease (Crohn's disease). (1991) (1)
Intestinal involvement in sarcoidosis. (1993) (1)
P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE (2013) (1)
Rectal bleeding accurately reflects mucosal inflammation in patients with Ulcerative Colitis (2015) (1)
T1135 Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo-Controlled Trials (2008) (1)
Anti-Microbial Antibodies and Inflammatory Markers are Present in the Serum of Patients with IBD Years Before Diagnosis and can Predict Disease (2017) (1)
Decreased frequency of HLA-DR3 in fistulising Crohns disease (1999) (1)
P0121 PP ENVIRONMENTAL RISK FACTORS IN INFLAMMATORY BOWEL DISEASE (IBD): A PEDIATRIC POPULATION-BASED CASE-CONTROL STUDY (2004) (1)
P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (1)
Health-Related Quality of Life Improvements in Patients with Active Crohnʼs Disease Following Treatment with Certolizumab Pegol in the MUSIC Study (NCT00297648): 1157 (2010) (1)
Safety of Adalimumab in Global Clinical Trials of Patients with Crohnʼs Disease: 1142 (2010) (1)
Tu1105 Development of the Crohn's Disease (CD) Digestive Damage Score: The LéMann Score (2013) (1)
P317 Characterisation of patients with delayed response to ustekinumab for Crohn’s disease (2019) (1)
Increased Sero-Reactivity to Antigens of Firmicutes Flagellin Prior to Diagnosis of Crohn's Disease (2017) (1)
Jejunal Secretion of Immunoglobulins in Patients With Crohns-disease (1986) (1)
Sa1251 Recurrence of Crohn's Disease After Definitive Stoma: A Retrospective Study in 83 Patients (2012) (1)
Safety and Effectiveness of Combining Biologics and Small Molecules in IBD: Systematic Review With Meta-Analysis (2021) (1)
[Physiopathology of inflammatory bowel diseases: new biological tools for disease diagnosis and monitoring?]. (2003) (1)
Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohnʼs Disease Patients: 842 (2005) (1)
[Confocal endoscopy]. (2005) (1)
LINKAGE ANALYSIS OF CHROMOSOME 12 LOCI IN CROHN'S DISEASE FAMILIES. (1998) (1)
558 Influence of Symptom Knowledge and History on Disease Scoring With the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2013) (1)
Peripheral Arterial Disease is Associated with an Increased Risk of Elderly-Onset Inflammatory Bowel Disease (2017) (1)
Phenotypic concordance and time clustering of diagnosis in multiply affected ibd families : the IOIBD Multiplex Family Collaborative Project, phases I a II (2005) (1)
Sa1777 - Combined Clinical and Biological Response (Concomitant Crp and Fecal Calprotectin Reductions) in Induction and Maintenance from the Phase 3 Ustekinumab Crohn's Disease Studies (2018) (1)
Poster PresentationsP011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS (2008) (1)
Editorial: de novo inflammatory bowel disease following bariatric surgery—potential implications for research and clinical practice. Authors’ reply (2018) (1)
Su1849 THE SAPPHIRE REGISTRY: SAFETY OF IMMUNOSUPPRESSION IN A PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF CANCER (2020) (1)
T1305 Are Anti-TNFS Able to Close Enterocutaneous Fistula in Crohn's Disease? (2010) (1)
Need for Caution in Diagnosis of Irritable Bowel Syndrome in Patients With Inflammatory Bowel Disease. (2017) (1)
[Intramural hematoma of the duodenum complicating acute pancreatitis. Contribution of magnetic resonance imaging]. (1992) (1)
Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy: 1022 (2007) (1)
Sa1895 VALIDATION OF THE LÉMANN INDEX IN CROHN'S DISEASE (2020) (1)
Mo1790 Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension (2016) (1)
Gut translocation in humans. (1995) (1)
P006 - Sustainability of adalimumab in improving the quality of life of patients with fistulizing Crohn's disease: 3-year data from CHARM (2009) (1)
Mo1899 Evaluation and Long-Term Benefit of Deep Remission in Crohn's Disease Patients Treated With Infliximab (2016) (1)
O-10: Increase of inflammatory bowel disease incidence in teenagers in a prospective population-based study during a 21-year period (1998–2008) (2014) (1)
P114 Adalimumab Safety in Crohn's Disease: A Sub-Analysis of Immunosuppressant and Steroid Use in the Charm Trial (2007) (1)
Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease (2019) (1)
[Rhabdomyosarcoma complicating celiac disease]. (1995) (1)
735 - Disease-Specific Antibodies and Proteomic Markers Allow for Early Detection of Asymptomatic IBD Years Before Diagnosis – Results from the Predicts (Proteomic Evaluation and Discovery in an IBD Cohort of Tri-Service Subjects) Study (2018) (1)
T1012 Long-Term Maintenance of Clinical Remission With Reduced Dosing Frequency of Adalimumab in Patients With Moderate to Severe Crohn's Disease (2010) (1)
611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE (2021) (1)
7 Statins Associated With Decreased Risk of New Onset IBD (2015) (1)
S0645 Efficacy and Safety of Ustekinumab for Crohn's Disease Through 5 Years: Final Results From the IM-UNITI Long-Term Extension (2020) (1)
Ulcerative colitis: Natural history—an optimistic message from Norway (2009) (1)
Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE: P‐58 (2012) (1)
Early Responses in Patient-reported Outcomes Are Predictors for Mucosal Healing in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Golimumab: Results from PURSUIT SC Induction: 1723 (2013) (1)
A new blood biomarker of endoscopic disease activity: a step forward in the treat-to-target paradigm for Crohn's disease? (2019) (1)
Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease (2011) (1)
Exploring life before IBD (2012) (1)
P403 Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE (2012) (1)
Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature. (2021) (1)
Induction of Remission with Adalimumab in Patients with Moderate Crohnʼs Disease: Subanalysis of CLASSIC I: 1166 (2011) (1)
Editorial: post hoc analysis of SONIC trial – authors’ reply (2015) (0)
Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB (2021) (0)
Safety of Adalimumab in patients with Crohnʼs Disease: Analysis of global clinical trials: P-0049. (2008) (0)
Fluorescence endoscopic imaging study of anastomotic recurrence of Crohn's disease after right ileocolonic resection (1995) (0)
P081 Clinical and phenotypic characteristics of ulcerative colitis at diagnosis according to age: A population-based study (2012) (0)
Secretion ofimmunoglobulins andplasmaproteins fromthecolonic mucosa: an invivostudy inman (1995) (0)
P024 PATIENT AND HEALTHCARE PROVIDER VIEWS ON ULCERATIVE COLITIS TREATMENT GOALS AND QUALITY OF LIFE: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (0)
Vedolizumab Demonstrates Early Symptomatic Improvement in Crohnʼs Disease (CD): A GEMINI 2 Post hoc Analysis: 668 (2017) (0)
Un syndrome occlusif énigmatique (1988) (0)
Mo1214 Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension (2014) (0)
35. Crohn's Disease (2014) (0)
Su1845 – Home Infusion of Biologic Medications in Patients with Inflammatory Bowel Disease is Associated with Higher Risk of Adverse Outcomes Than Hospital-Based Infusion: A Case-Control Study (2019) (0)
Recto-colic toxicity of non steroidal anti-inflammatory drugs (1995) (0)
Concomitant use of adalimumab and immunomodulators or corticosteroids compared with adalimumab alone (2011) (0)
RXR and PPARγ nuclear receptors exert a synergistic anti-inflammatory effect. Potential role in ulcerative colitis (UC) (2000) (0)
Infliximab vs. Ustekinumab in Biologic Naive Crohn's Disease. (2021) (0)
P362 Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics (2021) (0)
Optimal C-Reactive Protein Cutoff Point for Predicting Hospitalization in Patients With Moderately Active Crohn's Disease (2011) (0)
[Inflammatory bowel diseases: genetic hypothesis]. (1994) (0)
P084 AN EVALUATION OF THE CLINICAL COURSE AND UTILIZATION PATTERNS FOR ACUTE AND CHRONIC POUCH-RELATED CONDITIONS AMONG PATIENTS TREATED IN A MULTICENTER COHORT (2019) (0)
757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
Su1966 BIOLOGIC INITIATION WITHIN 12 MONTHS OF DIAGNOSIS WITH MODERATE-TO-SEVERE CROHN'S DISEASE IS ASSOCIATED WITH DECREASED HOSPITALIZATION, OUTPATIENT VISITS, AND ER VISITS: AN ANALYSIS OF REAL-WORLD HEALTH CLAIMS DATA (2020) (0)
P213 Agreement between Crohn's disease endoscopy severity scores derived from live local, delayed local video-recorded and central readings. (2017) (0)
Idiopathic chronic calcifying pancreatitis and giant pancreatic stones. (1990) (0)
Clinical Benefit of Adalimumab Dose Adjustment for Patients With Moderately to Severely Active Crohn’s Disease in EXTEND: 1610 (2014) (0)
Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: 1614 (2012) (0)
Clinical Course of Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis: Results of a National Multicentre Study (2011) (0)
P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease (2019) (0)
P660 Crohn's disease course is not different in familial than in sporadic cases: A case-control population-based study (2014) (0)
Adalimumab 160-/80-mg Induction Regimen is Associated With Better Outcomes Compared With the 80-/40-mg Regimen During Maintenance Therapy in Patients With Crohn's Disease (2011) (0)
High level expression of PPARγ in differentiated colon epithelium (1998) (0)
Mo1243 Post-Operative Complications in Pediatric Inflammatory Bowel Disease: A Population-Based Study (2013) (0)
CYTOSTEATONECROSE DISSEMINEE D'ORIGINE PANCREATIQUE (1993) (0)
Survival and multiplication of adherent-invasive E. coli strains isolated from patients with Crohn's disease (CD) in the J774 murine macrophage-like cell line (2000) (0)
Epithelial Neutrophilic Infiltrate - The Rising Star in Ulcerative Colitis. (2021) (0)
Adalimumab Induced and Maintained Clinical Remission in Patients with Crohnʼs Disease Independent of Baseline CRP Concentration: Subanalysis of the CHARM Study (2006) (0)
Sa1213 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
P378 Safety of adalimumab in global clinical trials of ulcerative colitis patients (2013) (0)
Mechanisms of steroid-refractory disease in IBD (2005) (0)
[Fungal intestinal flora in the development of Crohn's disease]. (2013) (0)
T1685 Mucosal Lymphangiogenesis: An Integral Component of Inflammatory Bowel Disease Pathogenesis (2009) (0)
No evidence for genetic anticipation in Crohn's disease (1997) (0)
Attenuation of colon infiammation through the RXR/PPARγ heterodimer: A basis for new therapeutic strategies (2001) (0)
Endoscopic fluorescence imaging for early assessment of anastomotic recurrence of Crohn's disease (1999) (0)
Pancreatic damages in TNBS-induced colitis in mice (2000) (0)
Answer to the letter by Rodriguez-Lago et al: Pre-inflammatory bowel disease: back to the future. (2020) (0)
Su1864 - Clustering of Crohn's Disease within Affected Jewish Sibships (2018) (0)
Efficacy and safety of certolizumab pegol in patients with prior Influximab use: O-0017 (2007) (0)
Sa1295 Development of Process and Outcome Quality Indicators for Inflammatory Bowel Disease (IBD) (2012) (0)
P873 The psycho-emotional experience of pregnancy in women with IBD and correlation with gut microbiome (2018) (0)
Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation who were naïve to anti-TNF treatment: 5-year results from PRECiSE 4: P-41. (2011) (0)
[Epidemiology and genetics of inflammatory bowel diseases]. (1991) (0)
DOP005 Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis. (2017) (0)
P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial (2019) (0)
P071 LACK OF EFFECT OF CONCOMITANT IMMUNOSUPPRESSANT AND/OR CORTICOSTEROID TREATMENT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: ANALYSIS OF CERTOLIZUMAB PEGOL DATA (2008) (0)
[Inflammatory bowel diseases: a disease of the century]. (2005) (0)
Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS (2021) (0)
Oligomannosides of synthesis, their preparation and their use in the detection of antibodies and for the prevention of infections (1999) (0)
P-017 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis (2016) (0)
Su1898 - Emergent Colectomy Rates Decreased While Elective Ileal Pouch Anal Anastomosis Rates Were Stable over Time: A Nationwide Inpatient Sample Study (2018) (0)
[Anti-TNF agents in inflammatory bowel disease: indications and management]. (2004) (0)
DOP064 High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitis. (2017) (0)
OP04 Mortality and cancer in paediatric inflammatory bowel disease: A population-based study (2012) (0)
PTH-065 Effect of vedolizumab treatment on extraintestinal manifestations in patients with crohn’s disease: a gemini 2 post hoc analysis (2017) (0)
P-137 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients (2013) (0)
Is endoscopic ultrasonography helpful before ERCP in the management of patients at risk of biliary obstruction (1998) (0)
Reply to Letter to Editor by Dr. Uemura et al. (2021) (0)
Opportunistic infections and anti-tumor necrosis factor antagonists in patients with IBD: prevention and diagnosis (2008) (0)
Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY (2021) (0)
The Chicago Classification of Pouchitis: An Important Step Towards a Needed Consensus. (2021) (0)
Survival and multiplication of adherent-invasive Escherichia coli strains isolated from patients with Crohn's disease (CD) in the J774 murine macrophage-like cell line (2001) (0)
P137 Clinical and pathological correlations between primary and secondary ileal strictures in Crohn’s disease (2018) (0)
Reply (2021) (0)
Thiopurine S-methyltransferase deficiency associated with a novel mutation. (2010) (0)
Concomitant Use of Adalimumab and Immunomodulators or Corticosteroids Compared with Adalimumab Alone: Pooled Safety Analysis: 2010 Presidential Poster: 1141 (2010) (0)
Tu1754 – Safety and Tolerability of Bt-11, a Gut-Restricted Lancl2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase I Study in Normal Healthy Volunteers (2019) (0)
Sa1792 PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES WITH VEDOLIZUMAB VERSUS ADALIMUMAB TREATMENT OF ULCERATIVE COLITIS: RESULTS OF THE VARSITY TRIAL (2020) (0)
133 INFLUENCE OF EARLY LIFE FACTORS ON THE DEVELOPMENT OF INTESTINAL MICROBIOTA OF INFANTS BORN TO MOTHERS WITH AND WITHOUT IBD (2020) (0)
O02 Peroxisome Proliferator-Activated Receptor Gamma Functions as an Antibacterial Factor (2007) (0)
Sa1881 – Effects of Intravenous Vedolizumab on Health-Related Quality of Life and Work Productivity in Patients with Crohn’s Disease: Results from the Phase 3B Versify Trial (2019) (0)
P026 SAFETY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: A META-ANALYSIS OF PLACEBO-CONTROLLED TRIALS (2008) (0)
Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease (2011) (0)
Su1287 Anal Neoplasia in Inflammatory Bowel Disease Is Associated With HPV and Perianal Disease (2015) (0)
P163 TRANSITION TO BIOLOGIC HOME INFUSIONS IN IBD PATIENTS IS ASSOCIATED WITH HIGH DROP OUT WITHIN ONE YEAR (2018) (0)
716 Early Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY (2019) (0)
P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis (2019) (0)
No evidence for involvement of the mitogen-activated protein kinase (MAPK) P38 and JNK pathways in human inflammatory bowel diseases and experimental colitis (2003) (0)
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis (2021) (0)
Infliximab Therapy Reduces Hospitalizations in Ulcerative Colitis Patients: 847 (2005) (0)
DOP059 Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's disease (2014) (0)
Hospitalization Rates in Patients with Crohnʼs Disease and Deep Remission: Data from the 56-week CHARM Trial: 1813 (2013) (0)
Infliximab Re-Introduction after Temporary Discontinuation: A Multicentric Survey (2017) (0)
Tu1169 Crohn's Disease Course Is Not Different in Familial Than in Sporadic Cases: A Case-Control Population-Based Study (2014) (0)
Toward Personalized Therapy in Inflammatory Bowel Disease (2019) (0)
P030 Continuous Adalimumab Maintenance Therapy Yields Better Outcomes than Induction and Reinitiated Therapy for Moderate to Severe Crohn's Disease: Subanalysis of Charm (2008) (0)
P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States (2021) (0)
453 Increased interleukin-10 and interluekin-4 mRNa expression in gut mucosa from patients with allergic asthma (2000) (0)
P320 The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry (2014) (0)
Laparoscopic surgery reduces peroperative opiold requirement in Crohn's disease (2000) (0)
P314 Long-term fate of the excluded rectum in Crohn’s disease (2019) (0)
[Eosinophil pleurisy revealing carcinoid tumor (2 cases)]. (1994) (0)
Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2021) (0)
Familial Crohn's disease: Is there genetic anticipation? (1996) (0)
Tu1802 - Disease Demarcation in Ulcerative Colitis is Associated with Different Patterns of Gene Expression (2018) (0)
Tu1930 Cats-1 Study: Immunomonitoring and Clinical Results of Treg Cell Therapy for Crohn's Disease (2012) (0)
S1187 Genetic Association Between Crohn's Disease and a Marker Located in the Region of Claudin 2 Implicates the Intestinal Barrier As a Primary Risk Factor in a Swedish Population (2009) (0)
Mo1595 Farnesoid X Receptor Expression is Inversely Correlated With Neoplastic Progression in Colitis-Associated Colon Carcinogenesis (2012) (0)
O-0017: Efficacy and safety of certolizumab pegol in patients with prior Influximab use (2007) (0)
442 Cancer Recurrence With Immunosuppressive Therapy in Immune Mediated Diseases: A Systematic Review and Meta-Analysis (2016) (0)
P216 IBD Patients' Need in Quality of Health Care (QoHC) ECCO Consensus (2008) (0)
Sa1879 – Disability in Patients with Ileal Pouch Anal Anastomosis (2019) (0)
Mo1254 Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Challenging Association (2014) (0)
Cholecystokinin release andbiliopancreatic secretion inresponsetoselective perfusion oftheduodenal loop withaminoacids inman (1988) (0)
DOP012 Disease demarcation in ulcerative colitis is associated with different patterns of gene expression (2018) (0)
23 EMERGENT COLECTOMY RATES DECREASED WHILE ELECTIVE IPAA RATES WERE STABLE OVER TIME: A NATIONWIDE INPATIENT SAMPLE STUDY (2018) (0)
280 THIOPURINE USE IN IBD IS ASSOCIATED WITH A STRONG IMPACT ON B CELLS PROVIDING FURTHER EXPLANATION FOR INCREASED EFFICACY OF ITS COMBINATION THERAPY WITH ANTI-TNF. (2020) (0)
No bacteria detected by PCR in mesenteric lymph nodes from patients with Crohn's disease (CD) (1998) (0)
TOUCH® PRO Study: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: P‐65 (2012) (0)
Has the mesenteric tissue an inflammatory role in Crohn's disease? (1998) (0)
Sa1786 – Assessment of Metal Exposures in Deciduous Teeth of Patients with Inflammatory Bowel Disease (2019) (0)
Su1921 - Clinical and Pathological Correlations Between Primary and Secondary Ileal Strictures in Crohns Disease (2018) (0)
PGI37 Finalisation and Psychometric Validation of a new Questionnaire Measuring Patient Satisfaction With Anti-TNF Treatments in Severe Crohn's Disease (2012) (0)
Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease (2019) (0)
Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS (2021) (0)
OP18 Long-term outcome after first intestinal resection in paediatric-onset Crohn's disease: A population-based study (2012) (0)
TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: 1130 (2009) (0)
P404 Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts (2019) (0)
Compassionate Use of Certolizumab Pegol in Patients with Crohnʼs Disease Who Have Failed Previous TNF Inhibitor Therapies: 1149 (2010) (0)
M1140 Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis in General Population: Frequency, Phenotypes and Clinical Course (2009) (0)
Mesenteric adipose tissue: A major source of TNFA in experimental ileitis in rats (2000) (0)
CARD4/NOD1 in inflammatory bowel disease. (2002) (0)
PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease (2012) (0)
P040 ONCE-OR TWICE-DAILY MMX MESALAZINE (2.4G/DAY) IS EFFECTIVE FOR THE MAINTENANCE OF REMISSION OF MILD-TO-MODERATE ULCERATIVE COLITIS REGARDLESS OF THE MESALAZINE DOSE OR REGIMEN USED TO INDUCE REMISSION (2008) (0)
Bronchopulmonary Manifestations in Inflammatory Bowel Diseases: A Retrospective Study From the GETAID (2011) (0)
Tu1956 Added Value of Diffusion-Weighted Imaging for Inflammation Assessment in Crohn's Disease (2016) (0)
Jejunal and serum anti-gliadin IgA in adult coeliac disease (1990) (0)
P 014 Behçet's disease mimicking Crohn's disease: a study of two generations (1993) (0)
Immunological Findings in Jejunal Secretion of Patients With Crohns-disease (cd) (1986) (0)
847w PAP/Reg3β Triggers IL-17-Dependent Neutrophil Recruitment and Intestinal Inflammation (2010) (0)
Tu1827 - Fecal Calprotectin (FC) in Babies Born to Mothers with or without IBD and Correlation with Microbiome (2018) (0)
Sa1265 Adalimumab Serum Concentration As a Predictor for Clinical Efficacy in Ulcerative Colitis (2015) (0)
T1787 Replication of Crohn's Disease-Associated Adherent-Invasive E. coli Within Macrophages is Dependent on TNF-α and Impaired by TNF-α Antagonist (2010) (0)
Adalimumab maintains long-term remission through 2 years in patients with moderate to severe Crohnʼs Disease: P-0085. (2008) (0)
Tu1162 Efficacy and Safety of Adalimumab in Children With Crohn's Disease Previously Treated With Infliximab (2013) (0)
Sa539 COMPARISON OF 1-YEAR COLECTOMY RISK BETWEEN THE US AND KOREAN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: A PROPENSITY SCORE MATCHING ANALYSIS (2021) (0)
P145 Clinical and phenotypic characteristics of Crohn's disease in elderly people: A population-based study (2012) (0)
A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE (2018) (0)
Serosal vascular lesions in Crohn's disease (1995) (0)
P007 GAPS IN COMMUNICATION BETWEEN PATIENTS WITH ULCERATIVE COLITIS AND HEALTHCARE PROVIDERS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (0)
Correction to: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium (The American Journal of Gastroenterology, (2018), 113, 9, (1345-1354), 10.1038/s41395-018-0162-0) (2018) (0)
Safety of adalimumab in global clinical trials of patients with Crohn's disease. (2011) (0)
Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS (2021) (0)
169 A PATHOGENIC B CELL RESPONSE IN ULCERATUVE COLITIS THAT ASSOCIATES WITH TREATMENT RESISTANCE AND DISEASE COMPLICATIONS (2021) (0)
Letter: rationalising aminosalicylates in inflammatory bowel disease—authors' reply (2020) (0)
P013 Immunophenotyping of peripheral whole blood from 743 IBD patients identifies patterns of association between immune cell populations and T-cell subsets with disease occurrence, severity and medication use (2018) (0)
Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD) (2000) (0)
Letter: mucosal healing is associated with improved long‐term outcomes in Crohn's disease – authors' reply (2016) (0)
423 DYNAMICS OF INTESTINAL INFLAMMATION AND MICROBIAL DYSBIOSIS IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE AND THEIR INFANTS (2020) (0)
Mo1898 Continuation or Switch to Another Anti-TNFα After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNFα? (2016) (0)
Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naïve to anti-TNF treatment (2011) (0)
Reply to Drs. Waters and Ahmad (2011) (0)
TOUCH™ Study Patient Outcomes: Workforce Participation, Productivity and the Impact of Natalizumab: 1134 (2009) (0)
Genetics of IBD: Where do we stand? Introduction. (1998) (0)
Iconography : Pancreatic changes in TNBS-induced colitis in mice (2008) (0)
Intestinal Alpha-chain Protein and Secretory Component (sc) in Alpha-chain Disease (alpha-cd) (1992) (0)
[Amyloidosis AL of the breast in an ileal carcinoid tumor]. (1997) (0)
[Methanogenesis in man]. (1987) (0)
[Disseminated cytosteatonecrosis of pancreatic origin]. (1993) (0)
Paper alert. (2020) (0)
[Obstructive inflammatory fibroid polyp of the cardia]. (1995) (0)
Subject Index Vol. 32, Suppl. 1, 2014 (2014) (0)
P826 Lower socioeconomic status is associated with disability in inflammatory bowel disease patients (2018) (0)
Su1907 Exploring MEChanisms of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot (2016) (0)
Agreement Between Crohn's Disease Endoscopic Severity Scores Derived from Live, Video-recorded, and Central Readings. (2018) (0)
C-reactive protein (CRP), a novel adipocytokine overexpressed in mesenteric fat in Crohnʼs disease: P-0006 (2007) (0)
Tu1341 Combination Therapy With Infliximab and Azathioprine Improves Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone (2015) (0)
[Lymphomas of the colon complicating hemorrhagic rectocolitis]. (1995) (0)
Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease: P‐59 (2012) (0)
O-004 YI Antibiotics and Risk of New Onset Inflammatory Bowel Disease: A Meta-analysis (2013) (0)
Could Inflammatory Bowel Disease Regulate Multiple Sclerosis Course? (P05.108) (2012) (0)
P006 RICK/RIP2 Polymorphisms in Inflammatory Bowel Diseases (2009) (0)
The relationship between the presence of ASCA antibodies and increased intestinal permeability in Crohn's disease (1999) (0)
Mo1817 - The Psycho-Emotional Experience of Pregnancy in Women with IBD and Correlation with Gut Microbiome (2018) (0)
Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY (2020) (0)
Su1792 - Fecal Lactoferrin is a Reliable IBD Biomarker During Pregnancy (2018) (0)
Mo1864 ILEAL AND RECTAL ULCER SIZE IMPACTS ABILITY TO ACHIEVE ENDOSCOPIC REMISSION IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE SONIC TRIAL (2020) (0)
Specific TNFalfa mRNA and protein synthesis by mesenteric adipose tissue in Crohn's disease (1997) (0)
P023 CROHN'S DISEASE PRESENTATION IN PEDIATRIC PATIENTS (2009) (0)
Safety of switching systemic steroids to budesonide modified-release capsules in steroid-dependent patients with inactive Crohn's disease (2001) (0)
Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics (2021) (0)
O10 Association between IL23R, ATG16L1, IRGM and NOD2 Susceptibility Genes and Subphenotypes on a Large Cohort of IBD Patients (2009) (0)
1 Polymorphisms in the Mannose Binding Lectin Gene are Associated with Defective Mannose Binding Lectin Functional Activity in Crohn ’ s Disease Patients (2016) (0)
P584 Vaccination and risk for inflammatory bowel disease: results of a meta-analysis (2014) (0)
S0197 The Expansion of Fecal Microbiota Transplantation (FMT) in Medicine: A Clinical Trials Survey (2020) (0)
Benefits of Adalimumab dosage adjustment for patients with Crohnʼs Disease: An analysis of the CHARM study: P-0063. (2008) (0)
T1206 Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis of Controlled Trials with Individual Patient Data (2009) (0)
P-050 Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis (2017) (0)
Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohnʼs disease: P-35. (2011) (0)
Su1803 THE CLINICAL PHENOTYPE OF COLLAGENOUS COLITIS IS ASSOCIATED WITH T CELL RELATED GENETIC VARIANTS (2020) (0)
Corrigendum to ‘Optimising monitoring in the management of Crohn's disease: A physician perspective’ [Journal of Crohn's and Colitis volume 7 (2013) 653–669] (2014) (0)
P296 CATS1 study: Immunomonitoring and clinical results of Treg cell therapy for Crohn's disease (2012) (0)
Subject Index Vol. 30, Suppl. 3, 2012 (2013) (0)
Adalimumab is Effective for Inducing Clinical Remission at Week 4 Regardless of Baseline Corticosteroid Use: Pooled Analysis of Four Clinical Trials: 1181 (2010) (0)
Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis (2014) (0)
Effect of switching to budesonide on the quality of life of patients with steroid-dependent Crohn's disease (2001) (0)
Mo1220 Patient-Reported Symptom Measures Differ in Their Association With Mucosal Healing in Adults With Moderately to Severely Active Ulcerative Colitis: Results From ULTRA 1 and 2 (2014) (0)
Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohnʼs Disease Exacerbation Who Were Naïve to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study: 1153 (2010) (0)
P415 Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011. (2017) (0)
The changing epidemiology of paediatric inflammatory bowel disease: authors’ reply (2011) (0)
Neutrophil andeosinophil involvement ofthesmall bowelaffected bychronic alcoholism (1988) (0)
Intestinal cancer in patients with Crohn's disease relation with duration of inflammatory disease (1998) (0)
M1792 PPARγ Expression in the Colon is Modulated by Exogenous and Endogenous Steroids (2010) (0)
W1222 Cyclosporine a Treatment of Severe Steroid-Refractory Ulcerative Colitis During Pregnancy (2008) (0)
P393 Patient-reported symptom measures differ in their association with mucosal healing in adults with moderately to severely active ulcerative colitis: Results from ULTRA 1 and 2 (2014) (0)
603 IBD-ASSOCIATED DYSBIOSIS IN UNAFFECTED RELATIVES OF IBD PATIENTS EMERGES IN LATE ADOLESCENCE AND INCREASES WITH AGE (2021) (0)
P-074 YI Chemotherapy Tolerance and Oncologic Outcomes in Patients with Inflammatory Bowel Disease and Gastrointestinal Malignancy (2016) (0)
2114 Chemotherapy tolerance and oncologic outcomes in patients with inflammatory bowel disease and gastrointestinal malignancy: The Mount Sinai Hospital experience (2015) (0)
AGA Abstracts146 Validation of the Inflammatory Bowel Disease Disability Index in a Population-Based Cohort (2015) (0)
Sa1866 Mesenteric Lymphatic and Venous Vasculopathy in Crohn's Disease (2016) (0)
Su1221 Symptom Scores Do Not Accurately Reflect Level of Mucosal Inflammation in Patients With Crohn's Disease (2015) (0)
[Jejunal secretion of immunoglobulins and secretory component in three patients with primitive humoral immunoglobulin deficiency]. (1991) (0)
Familial Ménétrier's disease. (1989) (0)
Efficacy and Safety of Ustekinumab for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 3 Years: Presidential Poster Award (2018) (0)
Correlation Between Endoscopic and Histological Activity in Adults with Moderate to Severe Crohnʼs Disease: Data from EXTEND: 2016 ACG Presidential Poster Award: 739 (2016) (0)
P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease. (2017) (0)
Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT (2013) (0)
DOP087 The gut microbiota of pregnant women with Crohn’s disease and their babies is associated with abnormalities in the adaptive immune system: results from the MECONIUM study (2018) (0)
P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey. (2017) (0)
PYRAMID Registry: Long-term Safety of Adalimumab by Age in Patients With Crohnʼs Disease: 717 (2017) (0)
Successful Treatment with Infliximab of Refractory Pyoderma Gangrenosum in 2 Patients with Inflammatory Bowel Diseases (2007) (0)
Shifts in Vedolizumab Utilization Across the United States Are Associated With Improved Outcomes (2018) (0)
Defining Quality Indicators for Inflammatory Bowel Disease (IBD): 10 Processes to Ensure High Quality Care: 1222 (2011) (0)
United European Gastroenterology ( UEG ) Week in Vienna , Austria Chairperson : Remo Panaccione 1 Speakers : (2018) (0)
Impact of Adalimumab on Hospitalization Risk for TNF-Antagonist-Naive patients With Moderate to Severe Crohnʼs Disease: O-0002. (2008) (0)
S1252 Presentation and Long Term Follow-Up of Refractory Celiac Disease (RCD): Comparison of Rcd of Type I with Rcd of Type II (2008) (0)
[Lymphocytic gastritis and Menetrier's disease: one or two diseases?]. (2009) (0)
P-063 Psychosocial Burden Among Patients with IBD: Prospectively Collected Data from 2 Academic Institutions (2016) (0)
[Pathogenesis: immunologic, infectious and genetic aspects]. (1998) (0)
Mo1923 Polymorphisms in the Mannose Binding Lectin Gene Are Associated With the Defect of the Mannose Binding Lectin Functional Activity in Crohn's Disease Patients (2016) (0)
S1105 Psoriasis and Eczema Skin Lesions Associated with TNF-Blockade Therapy in IBD: Natural History and Clinical Characteristics (2009) (0)
Inflammatory Bowel Diseases (2003) (0)
Su1901 - Indefinite Dysplasia Carries a High Risk of Progression to High-Grade Dysplasia or Colorectal Cancer in Inflammatory Bowel Disease Patients Undergoing Surveillance: A 15-Year Longitudinal Cohort Study (2018) (0)
P177 Histological features in paired ileal resections in Crohn's disease patients. (2017) (0)
P101 SARCOPENIA IS ASSOCIATED WITH INCREASED RISK OF INFECTION IN IBD PATIENTS OLDER THAN 50 YEARS STARTING BIOLOGIC MEDICATIONS (2020) (0)
P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial (2017) (0)
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (2018) (0)
DATE AND ORDER OF BIRTH SUGGEST A ROLE FOR ENVIRONMENTAL FACTORS IN FAMILIAL CROHN'S DISEASE. (1998) (0)
P117 - Global safety of adalimumab in trials of patients with Crohn's disease (2009) (0)
Comparative Cost Analysis of Fecal Microbiota Transplant and Antibiotic Treatment for Recurrent Clostridium difficile Infection: 575 (2013) (0)
[Digestive hemorrhage disclosing systemic elastorrhexia]. (1987) (0)
28 P The Crohn's disease endoscopic score (CDES): A simple index for endoscopic severity of Crohn's disease evaluation (2002) (0)
PTU-111 Baseline C reactive protein is associated with disease progression in patients with Crohn's disease (2012) (0)
Qualitative Studyof Fecala1-Proteinase Inhibitor in NormalSubjectsand PatientswithCrohn's Disease (1988) (0)
Mo1947 - Inflammatory Bowel Disease-Associated Gut Microbiotas Impact Homeostatic and Pathogenic Intestinal Immune Responses in Gnotobiotic Mice (2018) (0)
The role of immunization in reducing infections in patients with IBD (2009) (0)
Sa1430 Immunochip Analysis Identifies Multiple Susceptibility Loci for Collagenous Colitis (2016) (0)
Past History of Bariatric Surgery Associated with Increased Risk of new Onset Inflammatory Bowel Disease (2017) (0)
Su1924 - Hormone Therapy for Cancer is a Risk Factor for IBD Reactivation (2018) (0)
S0664 Disease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis (2020) (0)
S3207 Time Trends in Gut Microbiome Clinical Trials in Gastroenterology (2020) (0)
164 - Vedolizumab Therapy Induces a Redistribution of CD4+ T Cells to Uninvolved Intestinal Mucosa in Patients with Inflammatory Bowel Disease (2018) (0)
High Rate of Advanced Neoplasia after Detection of Low-Grade Dysplasia in Inflammatory Bowel Disease Patients with Primary Sclerosing Cholangitis (2017) (0)
Protective effect of CYP2D6*4 allele in ulcerative colitis disease. (2000) (0)
Corrigendum: Statins Associated with Decreased Risk of New Onset Inflammatory Bowel Disease (2016) (0)
Sa1813 – Cuffitis is Associated with a Significant Risk of Ileal Pouch Anal Anastomosis Failure (2019) (0)
Tu1965 Discrepancies Between Patient-Reported Outcomes, Endoscopic and Histologic Appearance in Ulcerative Colitis (2016) (0)
[Late diagnosis of mucoviscidosis]. (1994) (0)
Su1897 TRANSMURAL HEALING WITH VEDOLIZUMAB IN PATIENTS WITH ACTIVE CROHN'S DISEASE (2020) (0)
Chemotherapy tolerance and oncologic outcomes in colorectal cancer (CRC) patients with and without inflammatory bowel disease (IBD). (2016) (0)
Ige receptor affects fecal flora, bacterial translocation and intestinal inflammation (2000) (0)
Su1876 - A Combination of Clinical, Serological and Genetic Factors Predicts Complicated Disease Course in Paediatric-Onset Crohn's Disease: Results from a Population-Based Study (2018) (0)
Acute Exposure of Small Induces Mucosal Leakage Synthesis Intestine to Ethanol and Prostaglandin E (1992) (0)
84 DIFFERENT ASSOCIATIONS OF HLA CLASS II GENES IN ADULTS AND CHILDREN CROHNʼS DISEASE (1995) (0)
Hypertrophic and Constrictive Ileal Strictures in Crohn's Disease: A Histomorphometric Analysis of Two Distinct Entities (2017) (0)
Tu1181 Vaccination and Risk for Inflammatory Bowel Disease: Results of a Meta-Analysis (2014) (0)
Histological Features in Paired Ileal Resections in Crohn's Disease Patients (2017) (0)
P017 Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Colectomy Analysis from ACT1 and ACT2 (2008) (0)
Su1936 - Hypertrophic and Constrictive Ileal Strictures in Crohn's Disease: A Histologic, Morphometric and Clinical Study (2018) (0)
[Spontaneous opacification of the bile ducts during an esophagogastroduodenal transit study in 2 brothers with duodenal Crohn's disease]. (1986) (0)
Mo1591 Farnesoid X Receptor Expression is Reduced in the Right Colon of Ulcerative Colitis Patients With Primary Sclerosing Cholangitis: A Potential Role in the Increased Risk of Right-Sided Colonic Neoplasia (2012) (0)
Nature Reviews UNCORRECTED PROOF (2014) (0)
335 – Vedolizumab Targets Lymphoid Aggregates in the Gastrointestinal Tract of Patients with Inflammatory Bowel Disease, Reflected by a Dramatic Drop in Gut-Homing Plasmablasts in Circulation (2019) (0)
P191 Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis (2018) (0)
Portal Vein Thrombosis in Inflammatory Bowel Disease (IBD) Patients: Analysis of a Retrospective Cohort of the GETAID (2011) (0)
Early Biologic Treatment of Crohnʼs Disease Slows Progression Rate of Change of Lemann Index of Cumulative Bowel Damage: 2016 ACG Presidential Poster Award: 696 (2016) (0)
Endoscopic recurrence after surgery in Crohn's disease (CD) is associated with IL-4 and IgE production (1997) (0)
P175 Post-operative complications in pediatric inflammatory bowel disease: a population-based study (2013) (0)
EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHNʼS DISEASE (ENACT-2): 788 (2004) (0)
565 TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF A PATHOGENIC B CELL RESPONSE IN ULCERATIVE COLITIS THAT ASSOCIATES WITH TREATMENT RESISTANCE AND DISEASE COMPLICATIONS (2020) (0)
Tu1894 IMPACT OF DISCONTINUING THIOPURINES AT ANTI-TNF INITIATION IN INFLAMMTORY BOWEL DISEASE: A NATIONWIDE DANISH COHORT STUDY (2020) (0)
Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohnʼs Disease Patients: Results from the IM-UNITI Maintenance Study: 2016 ACG Presidential Poster Award: 663 (2016) (0)
Time to Remission and Response in Adalimumab-treated Patients with Moderately to Severely Active Ulcerative Colitis from ULTRA 2: 1681 (2013) (0)
Refractory sprue maybe the missing link between celiac disease and enteropathy associated T-cell lymphoma. Clinical, pathological, phenotypic and molecular evidence in a national cooperative study (2000) (0)
P121 Antimicrobial antibodies and inflammatory markers are present in the serum of patients with IBD years before diagnosis and can predict disease. (2017) (0)
TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients: 1135 (2009) (0)
Reliability of celiac disease antibodies in te assessment of gluten-free diet adherence. (2010) (0)
Mo1806 – Endoscopic Pouch Activity in Asymptomatic Patients with an Ileal Pouch Anal Anastomosis is Associated with an Increased Risk of Future Pouchitis (2019) (0)
Mannose binding lectin modulates intestinal inflammation and Candida albicans colonization in mice (2014) (0)
FINE MAPPING OF THE INFLAMMATORY BOWEL DISEASE SUSCEPTIBILITY LOCUS 1(IBD1) ON CHROMOSOME 16. (1998) (0)
Endoscopic study of anastomotic recurrence of Crohn's disease: correlative findings by fluorescence imaging and histopathology (1999) (0)
DOP002 Trends in small bowel resections for Crohn's disease with and without short bowel syndrome in the era of biologics. (2017) (0)
Tu1715 Candida Albicans Colonization and Anti-Glycan Antibodies in Active and Quiescent Crohn's Disease (2013) (0)
Commentaries on "Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada": networking in pediatric inflammatory bowel disease: the French GETAID Pédiatrique experience. (2012) (0)
P286 Assessing preference for deep remission in patients with Crohn's disease (2012) (0)
Sa1832 – Crohn’s Like Disease of the Ileal Pouch Anal Anastomosis in Ulcerative Colitis – Incidence, Risk Factors and Outcomes (2019) (0)
Sa1229 Durable Clinical Remission and Response in Adalimumab-Treated Patients With Ulcerative Colitis (2015) (0)
Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation: 3-year results from the PRECiSE 4 study: P-0031. (2009) (0)
Sa1701 - A Multicenter Cohort Study to Assess the Safety of Vedolizumab for Inflammatory Bowel Disease (2018) (0)
P.73 ARE SMALL BOWEL ADENOCARCINOMA (SBA) COMPLICATING CROHN'S DISEASE (CD) ASSOCIATEDWITH DYSPLASIA? (2010) (0)
Su1085 Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's Disease (2014) (0)
Deep Remission With Vedolizumab in Patients With Ulcerative Colitis: Evaluating Various Combinations of Endoscopic and Patient-Reported Outcomes: 1629 (2014) (0)
Post‐Operative Complications in Pediatric Inflammatory Bowel Disease: a Population‐Based Study: P‐155 (2012) (0)
[Incidences of chronic inflammatory bowel diseases in France: the table is growing richer]. (1997) (0)
Expression of the mu-opioid receptor (MOR) is enhanced in inflammatory bowel diseases (IBD) and regulated by the NFkappaB pathway (2004) (0)
TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Crohn's Disease Severity: 1139 (2009) (0)
Tu1254 GLYCANS ARE DUAL REGULATORY ELEMENTS IN THE CROSSTALK BETWEEN MICROBIOME AND GUT IMMUNE RESPONSE. (2020) (0)
Increased incidence of crohn's disease in children in Northern France. Results of a prospective population-based study (1988–1999) (2003) (0)
PSY45 DEVELOPMENT OF A QUESTIONNAIRE TO EVALUATE TREATMENT SATISFACTION OF PATIENTS WITH SEVERE CROHN'S DISEASE: QUALITATIVE STEPS (2009) (0)
DOP003 Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort. (2017) (0)
P521 Efficacy and safety of adalimumab in children with Crohn's disease previously treated with infliximab (2013) (0)
Sa1776 - Sustained Corticosteroid-Free Remission with Vedolizumab in Moderate-to-Severe Ulcerative Colitis: A Post HOC Analysis of Gemini 1 (2018) (0)
Preoperative infliximab does not decrease the area of resected bowel at surgery in Crohn's disease (2003) (0)
Response to Cote-Daigneaut et al. (2016) (0)
TOUCH® Patient Reported Outcomes Study: The Impact of Natalizumab on Crohn's Disease Severity: P‐63 (2012) (0)
[Narrow band image videoendoscopy in gastroterology]. (2005) (0)
Sustained Remission With No Dose Escalation After Re-Induction With Certolizumab Pegol in Patients With Crohn's Disease Exacerbation Who Were NaïVE to Anti-TNF Treatment: 5-Year Results From Precise 4 (2011) (0)
1009 - Immunophenotyping of Peripheral Whole Blood from 743 IBD Patients Identifies Patterns of Association Between Immune Cell Populations and T-Cell Subsets with Disease Occurrence, Severity and Medication Use (2018) (0)
Mo1904 – Concomitant Steroid Therapy with Anti-TNF Therapy is Not More Effective Than Anti-TNF Monotherapy in Inducing Remission in Crohn’s Disease: A Systematic Review and Pooled Meta-Analysis of Placebo-Controlled Trials (2019) (0)
[Methotrexate treatment in Crohn disease]. (1992) (0)
Benefit-Risk Assessment of Adalimumab as Maintenance Treatment for Ulcerative Colitis: NEAR Analysis of Week 8 Responders in ULTRA 2: 1593 (2012) (0)
Immunochip Analysis Revealed HLA Mechanism in Collagenous Colitis and Overlapping Genes with Immunomediated Diseases (2017) (0)
Mo1900 Combination Therapy With Infliximab and Methotrexate Does Not Improve Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone (2016) (0)
Mo1810 - Lower Socioeconomic Status is Associated with Disability in Inflammatory Bowel Disease Patients (2018) (0)
[Eosinophilic gastroenteritis in a tropical area: report of a Congolese case]. (2005) (0)
Tu1933 Fecal Calprotectin Improves the Predictive Power of 3 Practical Indices for Mucosal Healing Among Patients With Crohn's Disease: Results From PREDICT (2016) (0)
Fecal Lactoferrin (fLac) and Calprotectin (fCal) as Surrogate Markers of Mucosal Healing: Post-hoc Analysis from the PURSUIT SC Induction Study: 1864 (2015) (0)
Su1847 ABDOMINAL VISCERAL-TO-SUBCUTANEOUS FAT INDEX IS ASSOCIATED WITH HIGHER RATES OF C. DIFFICILE INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) STARTING NEW BIOLOGIC MEDICATIONS (2020) (0)
Su1806 - Histological Severity of Ulcerative Colitis Correlated with Shorter Time to Disease Extension in a Subgroup of Patients with Limited Disease (2018) (0)
The Classical Immunosuppression : Overrated or Underused ? Deep Remission : A New Concept ? (2013) (0)
A199 EFFICACY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: RESULTS FROM THE OCTAVE CLINICAL TRIALS (2018) (0)
Sa467 THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD) PERFORMS BETTER THAN THE SES-CD FOR PREDICTION OF ENDOSCOPIC REMISSION IN CROHN'S DISEASE (2021) (0)
Original contributionReliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease (2003) (0)
Multicenter prospective validation of a simple endoscopic score for Crohn's disease (SES-CD) (2003) (0)
TOUCH® Patient Reported Outcomes Study: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients: P‐64 (2012) (0)
[Von Recklinghausen's neurofibromatosis associated with Zollinger-Ellison syndrome]. (1988) (0)
Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY (2021) (0)
Conjugal inflammatory bowel disease: a systematic review and European survey (2021) (0)
P207 One-year response and remission rates in ulcerative colitis patients with week 8 response to adalimumab: Subanalysis of ULTRA 2 (2012) (0)
Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis (2017) (0)
Tu1830 - Differences in the Microbial Composition in Cord Blood and Placenta by Maternal IBD Status (2018) (0)
Mo1840 - Benefit of Combination Therapy with Infliximab and Immunomodulators in Crohn's Disease is Primarily Driven by Pharmacokinetics (2018) (0)
ENACT-2 SAFETY, TOLERABILITY, AND IMMUNOGENICITY RESULTS OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE: 827 (2004) (0)
IL-8 in early and chronic ileal lesions of Crohn's disease (CD) (1998) (0)
Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award: 726 (2017) (0)
Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. (2021) (0)
Efficacy and Safety of Adalimumab in Moderate Compared with Severe Crohnʼs Disease: Pooled Data from the CHARM and EXTEND Trials: 1163 (2011) (0)
aware that they may be present, albeit in a lower range, in other immune disorders. (2001) (0)
Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis (2018) (0)
[Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?]. (1989) (0)
Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis: O-7. (2011) (0)
Subject Index Vol. 27, Suppl. 1, 2009 (2010) (0)
Mo1798 – Inflammatory Microheterogeneity in Uc: Implications for Microscopic Assessment of Disease Activity (2019) (0)
852 Cx601, Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells (eASC), for Complex Perianal Fistulas in Crohn's Disease: Results From a Phase III Randomized Controlled Trial (2016) (0)
Ulcerative Colitis: Today, Tomorrow, and the Future (2020) (0)
Mo1757 Evidence for a Role of Superantigens in the Pathogenesis of Ulcerative Colitis-Associated Primary Sclerosing Cholangitis (2015) (0)
110 – Stopping 5-Aminosalicylates in Crohn's Disease Patients Starting Biologic Therapy Does Not Increase the Risk of Adverse Clinical Outcomes: Analysis of Two Nationwide Population-Based Cohorts (2019) (0)
P571 Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis (2014) (0)
Tu1822 - The Gut Microbiota of Pregnant Women with Crohn's Disease and their Babies is Associated with Abnormalities in the Adaptive Immune System - Results from the Meconium Study (2018) (0)
Impact of Adalimumab (HUMIRA®) on Patient‐Reported Outcomes: 920 (2007) (0)
Sa484 OUTCOMES OF PASSABLE AND NON-PASSABLE STRICTURES IN CLINICAL TRIALS OF CROHN'S DISEASE: A POST-HOC ANALYSIS (2021) (0)
Adalimumab is effective for inducing clinical remission at week 4 regardless of baseline corticosteroid use (2011) (0)
Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis (2021) (0)
IVER IS THWARTED BY LOW INTEROBSERVER AGREEMENT CHAPTER 11 (2015) (0)
Su432 IMPACT OF THIOPURINE EXPOSURE ON IMMUNOGENICITY TO INFLIXIMAB IS NEGLIGIBLE IN THE SETTING OF ELEVATED INFLIXIMAB CONCENTRATIONS (2021) (0)
Mo1828 THE EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASES AMONG IMMIGRANTS TO DENMARK: A POPULATION-BASED COHORT STUDY (2020) (0)
Crohn ’ s disease course is not different in familial than in sporadic cases : A case control population-based study (2014) (0)
Stratification of Crohn’s Disease Patients Using the Lemann Index to Quantify Gut Damage: A 5-Year Prospective Study: ACG Governors Award for Excellence in Clinical Research Presidential Poster: 1766 (2014) (0)
Subject Index Vol. 33, Suppl. 1, 2015 (2015) (0)
Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis: 1858 (2015) (0)
Su2078 Concomitant use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis (2012) (0)
Preface (2010) (0)
Jejunal Secretion of Immunoglobulins and Secretory Component in 3 Cases of Immunoglobulin Deficiency (1991) (0)
[abstract] HYPERBARIC OXYGEN IN SEVERE PERINEAL CROHN'S DISEASE (1996) (0)
Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction: 1700 (2014) (0)
Su1249 Evaluation of NT-proBNP in Inflammatory Bowel Disease (2015) (0)
Sa083 SYMPTOMATIC IMPROVEMENT WITH VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE STRATIFIED BY DISEASE ACTIVITY AND PRIOR TUMOR NECROSIS FACTOR ANTAGONIST FAILURE: POST HOC ANALYSES FROM THE GEMINI 2 TRIAL (2021) (0)
Tu1342 Early Treatment With Infliximab for Crohn's Disease Patients (2015) (0)
Su1819 Intestinal Failure in Crohn's Disease: A Nationwide Hospitalization Analysis (2016) (0)
[Homogeneous groups of patients in Crohn's disease: reality or imagination?]. (1998) (0)
Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohnʼs Disease: 1235 (2011) (0)
DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease (2018) (0)
Environmental and genetic factors in the development of perinuclear-antineutrophil cytoplasmic antibody (pANCA) positive ulcerative colitis : a European twin study (2018) (0)
P422 Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1 (2018) (0)
Neonatal life events and the risk of inflammatory bowel disease. (2019) (0)
[Digestive manifestations of food hypersensitivity in adults]. (1991) (0)
Mo1296 Quality of Life for Patients With Deep Remission vs. Clinical Remission and Deep Remission vs. Absence of Mucosal Ulceration: 3-Year Data From CHARM/ADHERE (2013) (0)
Reply: To PMID 23644079. (2014) (0)
Efficacy and Safety of Certolizumab Pegol in patients with active Crohnʼs Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study: P-0066. (2008) (0)
Small-bowel ulcerations at wireless capsule endoscopy: go the whole way (2009) (0)
Association of Baseline C-Reactive Protein with Maintenance of Remission in Patients with Moderate to Severe Crohnʼs Disease Treated with Adalimumab: 1165 (2011) (0)
Sa1882 Changes of Seroreactivity to Gut Microbiota Predate the Diagnosis of Crohn's Disease (2016) (0)
[A case of protein-losing lymphocytic gastritis treated by omeprazole]. (1990) (0)
P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study (2019) (0)
[Crohn disease: will epidemiology find the key?]. (1993) (0)
Anti-saccharomyces cerevisiae mannan (ASCA) antibodies in inflamatory bowel disease (IBD) (2000) (0)
Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES (2021) (0)
Su1458 Intestinal Transplantation for Short Bowel Syndrome: Waitlist Time and Survival (2015) (0)
P078 Nutritional Status and Growth in Pediatric Crohn's Disease (CD): A Population Based Study (2009) (0)
P364 Efficacy of anti-TNF on severe postoperative endoscopic recurrence in Crohn's disease (2012) (0)
S2002 Predictors of Poor Outcome in Pediatric Crohn's Disease (2010) (0)
Accepted Manuscript Treatment with Biologic Agents has not Reduced Surgeries among Patients with Crohn ’ s Disease with Short Bowel Syndrome (2017) (0)
DOP040 Five-year colectomy data from the observational postmarketing ulcerative colitis study, a European registry for adults with ulcerative colitis treated with originator infliximab or conventional therapy (2018) (0)
P012 CERTOLIZUMAB PEGOL LONG-TERM SAFETY ADJUSTED FOR DURATION OF EXPOSURE: NOVEL DATA FROM THE DEVELOPMENT PROGRAMME (2008) (0)
P129 Elevated NTproBNP in patients with Crohn's disease (2012) (0)
Adalimumab Therapy maintains remission for up to 3 Years in patients with moderately to severely active Crohnʼs Disease: Results From an Open-Label Extension of CHARM: P-0121. (2009) (0)
Dealing with Our 'In-Vironment': New Aspects in IBD Pathogenesis and Therapy: Falk Symposium 183, Basel, May 2012 (2013) (0)
Phenotypic changes of intraeptihelial lymphocytes (IELS) in intestinal lesions of Crohn's disease (CD) (1998) (0)
W1089 Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease (2009) (0)
Mo1905 - Discontinuation of 5-Aminosalicylates after Starting Biologic Therapy in Patients with Ulcerative Colitis is not Associated with Adverse Outcomes (2018) (0)
T1047 Gender Variations in the Incidence of Pediatric Crohn's Disease: A Population-Based Cohort Study (2008) (0)
Baseline C-Reactive Protein is Associated With Disease Progression in Patients with Crohnʼs Disease: 1164 (2011) (0)
[Severe hepatitis, complicating heat-stroke induced by exertion, successfully treated by neuroleptic and anticholinergic agents]. (1995) (0)
Mo1795 FRAILTY IS ASSOCIATED WITH NATIONWIDE READMISSION MORTALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2020) (0)
Editorial: serologic microbial associated markers to predict Crohn's disease behaviour – authors’ reply (2016) (0)
166 The Impact of Concurrent HIV-1 Infection on the Management of Patients With Inflammatory Bowel Disease (2016) (0)
Certolizumab pegol efficacy is greater with more recent-onset Crohnʼs Disease: PRECiSE 2 results: P-0080. (2007) (0)
604 - Consecutive Negative Findings on Colonoscopy During Surveillance Predict a Low Risk of Advanced Neoplasia in Patients with Longstanding Colitis: Results of a 15-Year Multicenter, Multinational Cohort Study (2018) (0)
P-138 Sustained Efficacy in Patients with Ulcerative Colitis Treated with Adalimumab: Results from ULTRA 2 (2013) (0)
Sa1015 – High Smoking Cessation Rates in a Pharmacist-Led Clinic Embedded in an IBD Center (2019) (0)
S0663 Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: An Update of Results From the OCTAVE Clinical Trials (2020) (0)
P-0019: Long-Term safety of Certolizumab Pegol in Crohn's Disease: Integrated safety findings on serious adverse events of special interest (2008) (0)
A method of diagnosing inflammatory bowel disease (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jean–fréderic Colombel‡‡?

Jean–fréderic Colombel‡‡ is affiliated with the following schools:

Icahn School of Medicine at Mount Sinai

Jean–fréderic Colombel‡‡'s Academic­Influence.com Rankings

Why Is Jean–fréderic Colombel‡‡ Influential?

Jean–fréderic Colombel‡‡'s Published Works

Published Works

What Schools Are Affiliated With Jean–fréderic Colombel‡‡?

Jean–fréderic Colombel‡‡'s AcademicInfluence.com Rankings